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DAVID FERRIDAY: husband, father, soccer competitor, cancer survivor.
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MESSAGE FROM THE DIRECTOR
Welcome to our 2017 Year in Review, the accomplishments
report of the Earle A. Chiles Research Institute.
We are pleased to share with you our highlights from
an exciting year in cancer medicine and research. 2017
marked the 30-year anniversary of our institute. From
our humble beginnings, our team has grown to more
than 130 investigators and research personnel, including 19 faculty members recognized globally for their
pioneering contributions to cancer immunotherapy.
With the passing of another year, we find yet again
that a novel immunotherapy – adoptive cell therapy –
is named the Advance of the Year by the American
Society of Clinical Oncology. Through the development
of our adoptive cell therapy and genomics programs,
we are poised to offer genome-guided, personalized
immunotherapies to our patients.

WALTER J. URBA, M.D., PH.D.
Member, director and endowed chair of Cancer Research,
Earle A. Chiles Research Institute,
a division of Providence Cancer Institute
at the Robert W. Franz Cancer Center

Another important advancement of last year came
with the first approval by the Food and Drug
Administration for a cancer therapy based not on
tumor type or location, but on a shared genetic profile.
This immunotherapy – from which an estimated
60,000 cancer patients stand to benefit each year –
may represent a new standard of care, and we are
proud of our contributions to the revolutionary clinical
trial which prompted the accelerated FDA approval.
2017 was also a year of transformation for Providence
Cancer Center brought about by philanthropic

support. In tribute to our longtime friend and
benefactor, the center was renamed the Robert W.
Franz Cancer Center. As a former board member of
Providence Portland Medical Foundation, Bob gave
generously of his time and resources to support our
growing cancer program. Together with his sister,
Elsie Franz Finley, he was instrumental to our evolution
as a worldwide leader in cancer immunotherapy.
The Robert W. Franz Cancer Center is now part of
Providence Cancer Institute – a regional ministry
supporting the comprehensive cancer services of
Providence Health & Services throughout Oregon. And
as we plan for the future, construction is underway to
ensure we are equipped for state-of-the-art care and
translational research for many years to come.
When I reflect on our journey over the past three
decades, I am filled with gratitude for the many
friends and supporters who have joined us along the
way. And memories of those who have passed away
remind us that our job is not done.
Cancer does not quit, and neither do we. I invite you
to join us on our quest for a cancer-free future. With
your support, together we can finish cancer.
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NEW & NOTEWORTHY

NEW ADDITIONS AND NOTEWORTHY ACHIEVEMENTS
From left, Immuno-Histology
Core, Antitumor T-cell Response
Lab, and genomics team.
At right, Todd S. Crocenzi, M.D.

Adoptive cell therapy lab

Immuno-Histology Core
The application of immunohistochemistry to preclinical
and clinical research is critical to elucidating the
mechanisms of cancer immunotherapy. At the forefront
of this technology, Zhaoyu Sun, Ph.D., manager,
Immuno-Histology Core, advises our investigators on
imaging techniques to accomplish their research goals.
With expertise in immunohistology, quantitative image
analysis and multiplex immunofluorescence staining,
she oversees the incorporation of new antibodies for
investigation, the evaluation of new methods and
techniques, and quality control. Established in 2017,
the core is one of two components of the Immune
Monitoring Laboratory directed by Associate Member
William L. Redmond, Ph.D. Learn more on Page 38.

A sought-after recruit from the
National Cancer Institute, Eric Tran,
Ph.D., assistant member, Antitumor
T-cell Response Laboratory, joined
our faculty in 2017 to lead a
laboratory devoted to adoptive cell
therapy – a highly personalized
immunotherapy approach
celebrated as the Advance of the
Year by the American Society of
Clinical Oncology. Dr. Tran trained
under renowned physician scientist
Steven A. Rosenberg, M.D., Ph.D.,
chief of the NCI Surgery Branch,
with whom he contributed to
groundbreaking studies showing the effectiveness
of this treatment strategy in patients with cancer.
Learn more on Page 6.

Genomics expansion
Precision oncology – personalized cancer care aided
by genomic profiling – is a promising treatment
strategy for patients with cancer. By analyzing the
genetic profiles of patients’ individual tumors, clinicians
may be able to predict which therapies will offer the
greatest benefits. In 2017, we expanded our genomics
program to complement our steadfast integration of
genomics and immunotherapy. Computational and
systems biologist Brady Bernard, Ph.D., and genomic
scientist Brian Piening, Ph.D., join Carlo B. Bifulco,
M.D., our director of Translational Molecular Pathology,
in developing robust bioinformatics and genomics
support for our investigators. Learn more on Page 26.

New standard of care
A phase II clinical trial drew
national headlines in 2017 when
66 of 86 patients with cancer saw
their tumors shrink or stabilize in
response to immunotherapy. For
18 of the patients who responded
to therapy, their tumors vanished
completely. With nearly 77 percent
of patients benefiting from disease
control, the study’s novel design and notable responses in
patients with multiple tumor types captured the interest
of researchers across the country.

These results will likely establish a new
standard of care, with the potential for
up to 60,000 cancer patients annually to
benefit from this treatment approach.
As reported in Science and The New York Times,
study investigators found evidence that a checkpoint
immunotherapy was effective in treating patients whose
cancers shared a distinct genetic abnormality known
as mismatch repair deficiency – a defect in the ability
to repair damaged DNA, leading to the first instance
of approval by the Food and Drug Administration for a
cancer treatment based on genetic profile rather than
tumor type or origin in the body.
The study, which is ongoing, is led by Johns Hopkins
University in collaboration with six institutions across
the United States, including the Robert W. Franz Cancer
Center. Todd S. Crocenzi, M.D., associate member and
director of Gastrointestinal Oncology Research, was the
second investigator to enroll patients to the study.
“These results will likely establish a new standard of
care, with the potential for up to 60,000 cancer patients
annually to benefit from this treatment approach,”
said Dr. Crocenzi. Learn more on Page 24.
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Center of Hope Initiative
Donors did it! In 2013,
Providence Foundations
of Oregon launched the
Center of Hope Initiative,
a five-year, $65 million
campaign to support
services of Providence
Cancer Institute throughout
Oregon, including cancer
research, patient care and
operational priorities. In
2017, we exceeded this
goal ahead of schedule
thanks to the generosity
of donors. The initiative
also strengthened our
statewide partnerships with
community organizations
such as Safeway
Albertsons, Portland
General Electric, Providence
Hood to Coast Relay,
The Human Bean and
Susan G. Komen.
Philanthropic support
provides opportunity for
growth and aids our sustainability. Gifts have strengthened our endowment,
helping us recruit and retain more scientists and physicians. Plans are underway to
expand our laboratory space and recruit investigators to lead new areas of cancer
research and develop better therapies for patients with cancer.
Philanthropy was also instrumental in establishing Providence Guest House, a
30-room housing facility opened in 2015 for patients and their families who come
to Portland for care, and the 11-story expansion of cancer services and research
in 2008. In 2017, this facility was renamed the Robert W. Franz Cancer Center to
honor the single largest donor in Providence’s 142 years in Oregon. Learn more
on Page 42.

Since our founding 30 years ago, we
have helped advance both the science of
cancer research and the standard of care
for patients with cancer. From leading the global clinical trial of ipilimumab to
launching Oregon’s first adoptive cell therapy lab for patients with epithelial
cancers, our team has often been first in the world, or first in Oregon, to offer
promising immunotherapies to patients with cancer.

1987 Earle A. Chiles Research
Institute is founded
First in Oregon: Adoptive cell 1994
therapy for renal cancer

First in Oregon: gene-modified 1996
vaccine for breast cancer

1995 First globally: gene-modified
vaccine + adoptive cell
therapy for cancer
2000 First in Oregon: sipuleucel-T
for prostate cancer

First globally: IL-21 for 2004
melanoma and renal cancer

2006 First-in-human trial of anti-OX40
First-in-human trial of 2008
DRibble vaccine

First cancer immunotherapy,
ipilimumab, approved by FDA

2011

2009 First-in-human trial of SBRT +
IL-2 for melanoma and renal
cancer
2012 First in Oregon: nivolumab
for lung cancer

First globally: modified
Listeria vaccine for
glioblastoma

2014

First in Oregon: adoptive 2017
cell therapy lab for
epithelial cancers

2016 First globally: nivolumab +
varlilumab for ovarian cancer
First globally: nivolumab +
lirilumab for head and neck
cancer
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Team Ferriday
scores a win
over cancer
WHEN DAVID FERRIDAY was working on the 11-story expansion of cancer
services at Providence Portland Medical Center, he knew it was a project that could
improve the lives of patients with cancer. What the Portland architect could not foresee
was the personal significance it would have in his future.
Ferriday’s employer, ZGF Architects, was engaged to lead the project. “It was early
in my career. My role was limited to working on the inpatient floors with the interior
designer,” said Ferriday. Opened in 2008, the tower’s award-winning design brings
together cancer services and research, blending science and care for whole-person
healing. From top to bottom, windows and skylights carry natural light to patient
rooms and treatment spaces. “The public areas we provided outside of the patient rooms
resemble living rooms, with nice views for patients and their families,” said Ferriday.
“I can’t say I ever saw myself actually using them.”

Routine screening
A decade later, the 50-year-old husband and father of three underwent routine screening
for colon cancer. An avid soccer player, Ferriday was in excellent health. When the
colonoscopy revealed he had locally advanced cancer – stage III out of IV stages, he was
stunned. Scans showed a 7-centimeter tumor wrapped around the inside of his colon
and the invasion of nearby lymph nodes.
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Although deaths from colorectal cancer have dropped
steadily in recent decades, the disease remains one of the
most lethal forms of cancer with fewer than 65 percent
of patients surviving beyond five years. In 2017, an
estimated 140,000 people were newly diagnosed, and
more than 50,000 died from the disease.

“My care has been top
notch at every step.”
Ferriday’s primary care doctor referred him to
Providence. A patient of the cancer center he once helped
design, Ferriday met Medical Oncologist Anupama
Acheson, M.D. She recommended the standard of care
– chemotherapy and radiation as an attempt to shrink
the tumor, followed by surgery. She also offered Ferriday
the chance to participate in an immunotherapy clinical
trial designed for patients like him, one that was available
only at Providence.

Putting cancer on the defensive
Physician scientist Kristina H. Young, M.D., Ph.D.,
has studied the effects of radiation and immunotherapy
in colorectal cancer for more than a decade. After
completing her medical and doctoral training in Oregon,
the California native remained to pursue a fellowship in
translational radiation oncology at the Earle A. Chiles
Research Institute. In 2015, she joined its faculty to lead
her own laboratory, making Portland her home. The
following year she opened a phase II clinical trial testing
galunisertib, an experimental immunotherapy given as
an immune-boosting treatment prior to standard care, in
patients with stage II or higher colorectal cancer.
Galunisertib attacks cancer at multiple levels, from
mechanisms involved in cancer cell growth to the

reinforcement of patients’ anti-cancer immune responses.
With standard care, a mere 10 percent of patients
experience complete regression of their tumors. By
adding galunisertib before radiation and chemotherapy,
Dr. Young hoped the therapeutic trifecta would help
more patients respond to therapy.
For Ferriday, the timing and location could not have
been better. Dr. Young’s study is the first of its kind
worldwide. Of 50 patients planned to participate, he was
the second to enroll in the study. For two weeks, he took
galunisertib daily in the form of a pill. Then he started
radiation and chemotherapy. When it came time for
surgery, he had completed four weeks of immunotherapy
concurrent with chemoradiation, and experienced few
side effects.

A winning strategy
A defender on two Portland soccer teams, Ferriday
continued playing matches throughout his treatments.
“Physically it was hard, but it lifted my spirits immensely

to be supported and to just be out there,” said Ferriday.
Soccer enthusiasm runs deep in his household. His
16-year-old daughter Addie plays central midfield for
Lincoln High School, and another daughter rose to play
in a semi-professional league.
A native Oregonian, Ferriday grew up in Portland.
Like his daughter, he attended Lincoln. That’s where he
met Sally Tapanen through mutual friends. Years later,
they reconnected at a school function, and married soon
after. They were still newlyweds when they received his
devastating diagnosis. “Thinking you’re going to lose
your husband – it’s indescribable,” said Sally. “He tried
to not let anything stop him.”
With his family rallied around him, Ferriday
underwent surgery in February 2017. And what his
surgeons found was remarkable: his bulky tumor had
shrunk five-fold to 1.4 centimeters, and all his lymph
nodes were free of the disease. For Ferriday and his family,
Dr. Young’s strategy was a success. Surgeons excised the
remaining cancer and he was on his way to recovery.
Out on the field, he has a new
passion to share. “Because my
friends are all hitting the 50-year
mark, I am really on them about
getting screened for colon cancer,”
said Ferriday. “I feel so fortunate
to have health insurance through
Providence. My care has been top
notch at every step.”
Learn more about Dr. Young and
this study on Page 18.
From left, Addie Ferriday,
her dad David Ferriday and
his wife Sally Tapanen.
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Antitumor T-cell
Response Laboratory
As leader of the Antitumor T-cell Response
Laboratory, Eric Tran, Ph.D., is investigating
how adoptive cell therapy, or ACT, can be
optimized to mediate cancer regression.
For Dr. Tran, 2017 was a year of opportunity.
Recruited from the National Cancer Institute where
he studied under cancer immunotherapy pioneer Steven
A. Rosenberg, M.D., Ph.D., Dr. Tran joined the Earle
A. Chiles Research Institute in January and began
developing his lab. His newly created team, comprising
a postdoctoral fellow and three research associates,
is learning the specialized techniques of ACT he
mastered while at the NCI. They are developing
novel genome-guided T-cell therapies for patients
with advanced cancers.

Eric Tran, Ph.D., assistant member, Antitumor T-cell Response Laboratory

GENOME-GUIDED ACT
A highly personalized form of immunotherapy, ACT
harnesses the ability of the immune system to eliminate
cancer through the collection, amplification and
reinfusion of patients’ tumor-killing T cells. Dr. Tran
seeks to augment this promising approach with the
power of genomics.
In his treatment strategy, patients’ tumor samples
are obtained by surgical resection, and peripheral blood
samples are also collected. T cells known to induce
cancer regression are harvested from the samples, and
genomic sequencing is performed to identify any
DNA mutations in the tumors. Then Dr. Tran’s team
analyzes the ability of the T cells to recognize the genetic
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mutations discovered by genomic sequencing. T cells
with the greatest tumor-reactivity are expanded to vast
quantities, typically billions, before they are reinfused to
patients as highly specialized, anti-cancer armies. After
infusion, patients may receive other immunotherapies,
such as interleukin-2, which enhance the effectiveness of
their T cells.
To perform the genomic sequencing essential to this
approach, Dr. Tran is aided by Carlo B. Bifulco, M.D.,
member and medical director, Molecular Genomics, and
the bioinformatics team he oversees. A genetic mutation
of particular interest to Dr. Tran is KRAS G12D, a
mutation common to multiple cancers which bears
potential as a therapeutic target of ACT, as reported by
Drs. Rosenberg and Tran in the New England Journal of
Medicine.

A major hurdle facing the field of
cancer immunotherapy is to define
mechanisms of immune resistance
in the tumor microenvironment, and
develop strategies to overcome them.
Dr. Tran will also partner with Brendan D. Curti,
M.D., member and director, Cytokine and Adoptive
Immunotherapy Program, to administer interleukin-2
and other immunotherapies, and with hepatobiliary and
pancreatic surgeon Pippa H. Newell, M.D., assistant
member and medical director of Providence Liver Cancer
Clinic, among other clinicians.
PROOF OF CONCEPT
NCI-supported research provided strong evidence that
cancer patients’ responses to checkpoint immunotherapy
are due in part to their tumor-reactive T cells. Clinical

trials conducted by Dr. Tran and colleagues provided
direct evidence that ACT can be effective in mediating
regression of advanced cancers, with two reports of
objective regression in patients with metastatic colorectal
cancer and metastatic bile duct cancer.
Despite recent progress, most cancer patients
are not cured by current immunotherapy. “A major
hurdle facing the field of cancer immunotherapy is
to define mechanisms of immune resistance in the
tumor microenvironment, and develop strategies to
overcome them,” said Dr. Tran. As noted in his Nature
Immunology article, the immunological targeting of
cancer mutations may represent the final common
pathway that results in cancer regression in response
to a variety of cancer immunotherapies. “Effectively
harnessing this pathway holds promise for improving
clinical outcomes in patients with metastatic cancers,”
said Dr. Tran.
In recognition of its potential to change treatment
paradigms dramatically, ACT was selected as the
Advance of the Year by the American Society of Clinical
Oncology. And for the potential impact his research may
have to advance cures for cancer, Dr. Tran was chosen
among 15 promising early-career scientists by the Sidney
Kimmel Foundation, which awarded him a two-year
research scholar grant.
FUTURE CLINICAL TRIALS
In collaboration with his colleagues, Dr. Tran is
developing clinical trials for patients whose cancers are
predicted to recur within three years. These include
pancreatic cancer and cholangiocarcinoma, cancers
with some of the poorest prognoses. “We hope to offer
patients this therapy as early as 2019,” said Dr. Tran.

PUBLICATIONS:
Lu YC, Zheng Z, Robbins PF, Tran E, Prickett TD,
Gartner JJ, Li YF, Ray S, Franco Z, Bliskovsky V,
Fitzgerald PC, Rosenberg SA. An efficient single-cell
RNA-seq approach to identify neoantigen-specific T
cell receptors. Molecular Therapy: the Journal of the
American Society of Gene Therapy. 2017; 26(2):379-89.
PMID: 29174843.
Patel SJ, Sanjana NE, Kishton RJ, Eidizadeh A, Vodnala
SK, Cam M, Gartner JJ, Jia L, Steinberg SM, Yamamoto
TN, Merchant AS, Mehta GU, Chichura A, Shalem O,
Tran E, Eil R, Sukumar M, Guijarro EP, Day C, Robbins P,
Feldman S, Merlino G, Zhang F, Restifo NP. Identification
of essential genes for cancer immunotherapy. Nature.
2017; 548(7669):537-42. PMID: 28783722.
Rosenberg SA, Tran E, Robbins PF. T-cell transfer therapy
targeting mutant KRAS. The New England Journal of
Medicine. 2017; 376(7):e11. PMID: 28199803.
Tran E, Longo DL, Urba WJ. A milestone for CAR T
cells. The New England Journal of Medicine. 2017;
377(26):2593-6. PMID: 29226781.
Tran E, Robbins PF, Rosenberg SA. Final common
pathway of human cancer immunotherapy: targeting
random somatic mutations. Nature Immunology. 2017;
18(3):255-62. PMID: 28198830.
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Basic Immunology
Laboratory
Andrew D. Weinberg, Ph.D., is a leading
expert in the immune-stimulating protein
OX40, also known as CD134, and its antibody
anti-OX40, an immunotherapy in development
for patients with cancer. He is investigating the
therapeutic effects of anti-OX40 therapy on a
newly identified immune cell population.
Understanding why the immune system fails to eradicate
tumors has been a goal of tumor immunologists for
decades. One approach to this vexing problem is to
identify tumor antigen-specific T cells in cancer patients,
and enhance the cells’ ability to eliminate cancer.
Dr. Weinberg’s team took up this strategy,
and their findings may have important
clinical implications.

Andrew D. Weinberg, Ph.D., member and Judith Ann Hartmann Endowed Chair
for the Laboratory of Basic Immunology

TUMOR ANTIGEN-SPECIFIC T CELLS
Antigens are proteins that alert the immune
system to the presence of harmful entities such
as viruses and tumors. CD8 T cells, a type of T
lymphocyte, are capable of recognizing antigens
produced by tumor cells – known as tumor
antigens, and launching an anti-cancer immune
response. However, when confronted with the immunesuppressing forces of the tumor microenvironment, the
T cells can be rendered ineffective. Identifying and
boosting patients’ tumor antigen-specific T cells is an
effective treatment strategy, made more effective by
counteracting tumor immune suppression.
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Dr. Weinberg’s team began by studying tumorinfiltrating T lymphocytes, or TIL, collected from
patients with solid tumors. “We reasoned that TIL
would be a good starting point to identify ongoing
tumor-specific T-cell responses,” said Dr. Weinberg.
Their reasoning led to a remarkable discovery: a new
subset of human CD8 T cells capable of recognizing
and killing tumors.
“Our studies revealed a novel population of CD8
T cells that is highly enriched for tumor-reactivity in
patients with solid tumors,” said Dr. Weinberg. “This
discovery represents a significant advance in the ability
to identify human tumor antigen-specific CD8 T cells
among a diverse population of TIL.”
The novelty of their discovery lies in the cells’ unique
characteristics: CD39 and CD103, two immune
activation markers, were present on the cells’ surfaces,
and the cells bear a gene expression signature which
appears to keep them confined within the tumor
microenvironment. These characteristics, among others,
indicate the cells experience chronic stimulation. While
they were capable of tumor antigen recognition, it seems
their ability to halt cancer progression was impaired.
Undeterred, Dr. Weinberg’s team dug deeper, looking
for answers in the laboratory. By analyzing expanded
T-cell subsets and a tumor cell line from the same
patient, they compared the tumor-killing potency of the
newly discovered cells to other T cells. In the lab, they
demonstrated that only T cells endowed with the CD39\
CD103 phenotype killed cancer cells. “Based on these
findings, focusing on this novel T-cell population may be
a promising approach to boost immune-mediated tumor
regression in patients with cancer,” said Dr. Weinberg.

ANTI-OX40 THERAPY
Examining the same T-cell population, Dr. Weinberg’s
team found that patients treated with anti-OX40 showed
higher frequencies of T cells bearing the CD39\CD103
phenotype than patients who received conventional
therapies. They hypothesized that patients whose TIL
contain higher frequencies of these cells will experience
greater overall survival.

We envision this work will provide a
partial road map for clinicians to treat
cancer patients with immunotherapy
for the next 10 to 20 years.
To test this premise, Dr. Weinberg’s laboratory is
collaborating with R. Bryan Bell, M.D., D.D.S., FACS,
and Rom S. Leidner, M.D., assistant members and
co-directors, Providence Head and Neck Cancer
Program, in a first-in-human clinical trial administering
anti-OX40 to patients with head and neck cancer prior
to surgery. By comparing patients’ tumor and blood
samples before and after surgery, they seek to determine
whether changes to these T cells following anti-OX40
therapy are associated with improved survival.
“Our hope is that these studies will increase our
understanding of how current immunotherapies affect
tumor-reactive T cells at the cellular and molecular
levels, and to guide the development of new therapies
for patients that fail current treatments,” said Dr.
Weinberg. “We envision this work will provide a partial
road map for clinicians to treat cancer patients with
immunotherapy for the next 10 to 20 years.”

PUBLICATIONS:
Bell RB, Feng Z, Bifulco CB, Leidner RS, Weinberg AD,
Fox BA. Immunotherapy. In: Bell RB, Fernandes RP,
Andersen PE, eds. Oral, Head and Neck Oncology and
Reconstructive Surgery. China: Elsevier; 2017: 314-40.
Duhen R, Weinberg A. Agnostic antibodies to costimulatory molecules. In: Butterfield LH, Kaufman HL,
Marincola FM, eds. Cancer Immunotherapy: Principles
and Practice. New York, NY: Demos Medical Publishing;
2017: 331-54.
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Cancer Immunobiology
Laboratory
Hong-Ming Hu, Ph.D., is studying the role of
autophagy – and antigen cross-presentation in
particular – in therapeutic vaccines for patients
with cancer.
Autophagy, the process by which cells recycle
dysfunctional components and eliminate intracellular
pathogens, is a long-standing focus of Dr. Hu’s research.
From the outset, his laboratory has investigated the role
of autophagy in cancer immunotherapy.
Therapeutic cancer vaccines have emerged as a viable
immunotherapy strategy. Like other vaccines, cancer
vaccines prompt an immediate immune response via
the innate immune system, while also stimulating an
adaptive immune response and long-term memory to
prevent cancer recurrence.
One approach to the development of cancer vaccines
is to extract proteins from tumor cells, and prime the
immune system to recognize the tumor proteins as
foreign. Tumor proteins, also known as tumor antigens,
can serve as targets of an effective immune response.
However, appropriate antigen selection is essential to
activating an effective immune response by vaccination.
Similarly, the selection of vaccine adjuvants, a substance
that enhances the body’s immune response to an antigen,
is critical to eliciting cancer immunity.

Hong-Ming Hu, Ph.D., associate member, Cancer Immunobiology Laboratory

NANOPARTICLES AS VACCINE ADJUVANTS
Seeking to develop more effective cancer vaccines,
Dr. Hu is evaluating the use of nanoparticles as vaccine
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adjuvants, and the function of nanoparticles in antigen
cross-presentation. Key to inducing cancer immunity by
vaccination, antigen cross-presentation entails the ability
of certain antigen-presenting cells to acquire, process and
present tumor antigens to CD8 T cells, converting naïve
CD8 T cells into activated cancer-killers.
As reported in Nanoscale Research Letters, Dr. Hu’s
lab found that positively charged superparamagnetic iron
oxide nanoparticles, or SPIO NPs, had a beneficial effect
on antigen cross-presentation and CD8 T-cell activation
compared to SPIO NPs with different chemistries.
“Nanoparticles modified with different chemistries
exhibit diverse biological properties and differ in their
adjuvant potentials,” said Dr. Hu. “This will make us
consider the design of effective and safe vaccine adjuvants
more carefully in the future.”
UBIQUITIN ENRICHES TUMOR ANTIGENS
While Dr. Hu is testing the ability of nanoparticles to
improve the immune responses of T cells, he is also
evaluating methods for effective tumor antigen selection
and extraction. One strategy is to analyze the role of the
ubiquitin pathway in antigen cross-presentation.
Ubiquitin, a small regulatory protein with autophagic
functions, modifies other cellular proteins through a
process known as ubiquitination, and tags mutated or
defective proteins for degradation. When appended to
proteins, ubiquitin can also act as an affinity tag, marking
the proteins for purification without the need for prior
identification of tumor antigens.
His lab examined the function of purified
ubiquitinated proteins derived from tumor cells,
and their findings, reported in the Journal of
Immunotherapy, shed light on the identification of

Our research demonstrates there is
potential to develop a shared immune
response by vaccination, and these
discoveries have application for the
next generation of cancer vaccines.
tumor antigens by means of antigen cross-presentation.
“Our studies establish that ubiquitinated proteins provide
a relevant source of tumor antigens for activating an antitumor immune response,” said Dr. Hu. “Ubiquitin can
be used as an affinity tag to enrich for patients’ unique
tumor-specific antigens, as well as shared tumor antigens
common to many types of cancer,” said Dr. Hu.
Their discovery may have significant implications for
cancer vaccine development, with the potential to invoke
immunity against many types of cancer.
CANCER VACCINES 2.0
Research by Dr. Hu’s lab has contributed to a better
understanding of the functions of nanoparticles and
ubiquitinated proteins in antigen cross-presentation, and
how they may be used to boost cancer immunity – a
partial representation of the advancements made by his
lab in illuminating the role of autophagy in cancer
immunotherapy.
“When designing cancer vaccines, scientists now
realize we need to identify patients’ unique tumorspecific antigens, as well as shared antigens, to optimize
immune responses,” said Dr. Hu. “Our research
demonstrates there is potential to develop a shared
immune response by vaccination, and these discoveries
have application for the next generation of cancer
vaccines.”

PUBLICATIONS:
Mou Y, Xing Y, Ren H, Cui Z, Zhang Y, Yu G, Urba
WJ, Hu Q, Hu H: The effect of superparamagnetic
iron oxide nanoparticle surface charge on antigen
cross-presentation. Nanoscale Research Letters. 2017;
12(1):52. PMID: 28102523.
Sanborn RE, Ross HJ, Aung S, Acheson A, Moudgil
T, Puri S, Hilton T, Fisher B, Coffey T, Paustian C,
Neuberger M, Walker E, Hu HM, Urba WJ, Fox
BA: A pilot study of an autologous tumor-derived
autophagosome vaccine with docetaxel in patients
with stage IV non-small cell lung cancer. Journal for
ImmunoTherapy of Cancer. 2017; 5(1):103. PMID:
29258618.
Yu G, Moudgil T, Cui Z, Mou Y, Wang L, Fox BA, Hu
HM: Ubiquitinated proteins isolated from tumor cells
are efficient substrates for antigen cross-presentation.
Journal of Immunotherapy. 2017; 40(5):155-163. PMID:
28368960.
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LABORATORY RESEARCH: Cancer Immunotherapy Laboratory

Cancer Immunotherapy
Laboratory
William L. Redmond, Ph.D., is investigating
how limiting or reversing tumor-induced
immune suppression, together with the
administration of immune-modulating
antibodies, may improve survival for patients
with cancer.

William L. Redmond, Ph.D., associate member, Cancer Immunotherapy Laboratory,
and director, Immune Monitoring Laboratory

Recent developments in cancer immunotherapy have
displayed its potential to improve overall patient survival,
particularly when therapies are combined and optimized
for maximum clinical benefit. Indeed, for certain cancers,
such as melanoma, lung cancer, advanced head and neck
cancer and some blood cancers, immunotherapy is now
regarded as a standard of care alongside chemotherapy,
radiation and surgery.
Yet, as reported in the European Journal of Cancer,
Dr. Redmond and colleagues describe several challenges
– from treatment dose, schedule and duration to the
need for clinical biomarkers – facing the field today.
“Even when immunotherapy agents are combined,
we find that some patients with cancer do not
experience clinical benefit, due in part to the immunesuppressing effects of the tumor microenvironment,”
said Dr. Redmond. “The next generation of cancer
immunotherapy will need to incorporate agents that
block or reverse immune suppression to improve overall
patient survival.”
Dr. Redmond’s lab is examining whether inhibition
of galectin-3, a protein known to promote cancer growth
and immune suppression, enhances the therapeutic
effects of immunotherapy.
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GALECTIN-3 INHIBITION
Found in a variety of cancer cells, galectin-3 is associated
with poor prognosis and is present at high production
levels in patients with metastatic cancer. Galectin-3 is
also known to attract myeloid-derived suppressor cells,
or MDSCs, a type of immune cell with regulatory and
suppressive functions. Tumors bearing high infiltration of
MDSCs have shown resistance to immunotherapy.

The next generation of cancer
immunotherapy will need to
incorporate agents that block or
reverse immune suppression to
improve overall patient survival.
Dr. Redmond’s team speculated that GR-MD-02,
a galectin-3 inhibitor, and anti-OX40, an immunestimulating antibody, would synergize to mediate cancer
regression. Using a preclinical model, they studied
the combination in cancers of the prostate, breast and
connective tissues. Compared to anti-OX40 therapy
alone, they observed the therapeutic combination was
more effective in reducing the frequency of MDSCs
within the tumor microenvironment, thus limiting
immune suppression and enhancing overall survival.
In other preclinical studies, they evaluated GRMD-02 with an anti-PD-1 antibody, a checkpoint
immunotherapy approved for several cancers, and found
additional evidence of clinical benefit. “Our studies
revealed that galectin-3 inhibition in conjunction with
immune-modulating antibodies enhanced tumor-specific
immunity and improved survival in preclinical models,”
said Dr. Redmond. “Our next step was to test these novel
combinations in patients.”

FIRST-IN-HUMAN CLINICAL TRIAL
In collaboration with Brendan D. Curti, M.D., member
and director, Cytokine and Adoptive Immunotherapy
Program, Dr. Redmond opened a first-in-human, phase I
clinical trial testing the safety and immunological effects
of GR-MD-02 in combination with pembrolizumab,
an anti-PD-1 antibody, in patients with melanoma,
lung cancer and head and neck cancer. The investigatorinitiated study is a collaboration of Providence Health &
Services and the pharmaceutical sponsor with support
from the National Cancer Institute.
Of the nine patients enrolled to the trial, five
experienced regression of their cancers in response
to therapy. “The clinical responses seen in this study
are encouraging, and we are making progress on
identifying immunological biomarkers that may predict
clinical responses,” said Dr. Redmond. “As our studies
demonstrate, patients who respond to the combination
of GR-MD-02 and pembrolizumab may have reduced
MDSCs following treatment – a potential biomarker
which may guide the development of future studies.”
Preliminary results from the clinical trial, along with
data from the corresponding preclinical studies, were
presented by Dr. Redmond’s laboratory at the 2017
annual meeting of the Society for Immunotherapy of
Cancer, which awarded the team a Young Investigator
Travel Award based on the quality of their research and
potential to advance the field.
Drs. Redmond and Curti plan to open another phase
I clinical trial in the future, testing GR-MD-02 and an
anti-OX40 antibody in patients with metastatic cancer,
to offer more patients hope for improved survival.

PUBLICATIONS:
Emens L, Ascierto P, Darcy PK, Demaria S, Eggermont
A, Redmond W, Seliger B, Marincola FM. Cancer
immunotherapy: opportunities and challenges in the
rapidly evolving clinical landscape. European Journal of
Cancer. 2017; 81:116-129. PMID: 28623775.
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LABORATORY RESEARCH: Integrated Therapies Laboratory

Integrated Therapies
Laboratory
As principal investigators of two R01 Research
Project grants from the National Cancer
Institute, Michael J. Gough, Ph.D., and Marka
R. Crittenden, M.D., Ph.D., are examining the
combination of highly targeted radiation
therapy with novel immunotherapies for
cancer. Together, they lead the Integrated
Therapies Laboratory.
The role of radiation therapy as an immunotherapeutic
agent is a subject of ongoing research. Yet preclinical
studies indicate high-dose radiation therapy is effective
in mediating cancer regression when paired with
immunotherapy.
In the prevailing theory, radiation therapy eradicates
cancer cells, which are processed by the immune
system, prompting an influx of cancer-killing CD8 T
cells to the tumor site. Checkpoint immunotherapies
counteract the immune-suppressing forces of the tumor
microenvironment, which enables the elimination of
residual cancer cells that survive radiation. Drs. Gough
and Crittenden tested this concept, and their findings
may guide the combination of these therapies for treating
patients with cancer.

Marka R. Crittenden, M.D., Ph.D., associate member, Integrated Therapies Laboratory,
and director, Translational Radiation Research, and Michael J. Gough, Ph.D., associate
member, Integrated Therapies Laboratory

RADIATION VS LISTERIA VACCINATION
The bacteria Listeria monocytogenes is in development as
a potential immune-based cancer therapy. One strategy
shown to generate anti-cancer immune responses uses a
modified form of Listeria as a cancer vaccine.
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In a preclinical pancreatic cancer model, Drs. Gough
and Crittenden compared high-dose radiation therapy
and a Listeria vaccine platform. They analyzed the ability
of both agents to generate anti-cancer immune responses
when combined with an anti-PD-1 antibody, a type
of checkpoint immunotherapy. They observed Listeria
vaccination prompted a greater increase in the number
of tumor-reactive T cells than radiation. However, the
vaccine failed to provide an advantage over radiation in
controlling tumor growth.
“In our experiments, generating large numbers of
tumor-reactive T cells by Listeria vaccination did not
substitute for the efficacy of radiation and an anti-PD-1
antibody,” said Dr. Gough. “This leads us to question
whether the main driver of radiotherapeutic efficacy is
to increase the number of CD8 T cells, and provides
guidance for future investigations.”
These findings, which confirm the benefits of
radiation therapy as a partner for checkpoint
immunotherapy, were presented by their lab at the
2017 annual meeting of the Society for Immunotherapy
of Cancer.
INNATE AND ADAPTIVE IMMUNITY
In other experiments, Drs. Gough and Crittenden are
using Listeria vaccination to study innate and adaptive
immune responses to cancer. Whereas the innate
immune system initiates immune responses, an adaptive
immune response can provide long-term immunity.
In a preclinical model, their lab evaluated an approach
to amplify the inflammatory immune response to Listeria
by modifying expression of suppressor of cytokine
signaling 1, or SOCS1, a protein known to suppress
inflammation. They reasoned loss of the SOCS1 protein

We demonstrated for the first time that
cell-specific loss of SOCS1 in dendritic
cells in vivo redirects the immune
response following Listeria vaccination
away from an adaptive response and
toward an innate response.
in dendritic cells, a cell that links innate and adaptive
immune responses, would boost immune activation and
increase T-cell responses.
By testing the Listeria vaccine in dendritic cells
engineered to lack SOCS1, they compared results from
in vitro experiments with those performed in living
organisms, known as in vivo experiments. Contrary to
their expectations, they observed a decrease in CD8 T-cell
responses. As reported in the Journal of Immunology,
dendritic cells lacking SOCS1 expression were functional,
but failed to generate an efficient adaptive immune
response. When the innate immune response increased,
the adaptive immune response decreased.
“We demonstrated for the first time that cell-specific
loss of SOCS1 in dendritic cells in vivo redirects the
immune response following Listeria vaccination away
from an adaptive response and toward an innate
response,” said Dr. Crittenden. “Strategies that aim
to generate cancer immunity by means of CD8 T-cell
meditation may need to avoid over-activation of crosspresenting dendritic cells to optimize the adaptive
immune response.”
Their discovery, albeit surprising, is yielding new
directions of research. Drs. Gough and Crittenden have
applied these insights to other areas of investigation in
their laboratory with the hope of improving therapies for
patients with cancer.

PUBLICATIONS:
Alice AF et al: Amplifying IFN-gamma signaling in
dendritic cells by CD11c-specific loss of SOCS1 increases
innate immunity to infection while decreasing adaptive
immunity. Journal of Immunology. 2018; 200(1):177185 [Epub 2017 Nov 17]. PMID: 29150567.
Baird JR et al: STING expression and response to
treatment with STING ligands in premalignant and
malignant disease. PLoS One. 2017; 12(11):e0187532.
PMID: 29135982.
Baird JR et al: Stimulating innate immunity to enhance
radiation therapy-induced tumor control. International
Journal of Radiation Oncology Biology Physics. 2017;
99(2):362-373. PMID: 28871985.
Patel AA et al: Early HPV-related base of tongue cancer.
In: Bell RB, Fernandes RP, Andersen PE, eds. Oral, Head
and Neck Oncology and Reconstructive Surgery. China:
Elsevier; 2017: 649-76.
Pryke KM et al: A novel agonist of the TRIF pathway
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Zika, Chikungunya, and Dengue viruses. MBio. 2017;
8(3):e00452-17. PMID: 28465426.
Sckisel GD et al: Differential phenotypes of memory
CD4 and CD8 T cells in the spleen and peripheral
tissues following immunostimulatory therapy. Journal
for ImmunoTherapy of Cancer. 2017; 5(33). PMID:
28428882.
Tormoen GW et al: The TAM family as a therapeutic
target in combination with radiation therapy. Emerging
Topics in Life Sciences. 2017; 1(5):493-500.
Weller M et al: Rindopepimut with temozolomide for
patients with newly diagnosed, EGFRvIII-expressing
glioblastoma (ACT IV): a randomised, double-blind,
international phase 3 trial. Lancet Oncology. 2017;
18(10):1373-1385. PMID: 28844499.
Eight of nine publications shown.

16

LABORATORY RESEARCH: Molecular and Tumor Immunology Laboratory

Molecular and Tumor
Immunology Laboratory
An expert in tumor immunology and
immune profiling, Bernard A. Fox, Ph.D., is
investigating immunotherapy mechanisms
of action and methods of tumor immune
escape. By developing novel biomarkers, his
lab is advancing technology which may help
clinicians predict patient responses to therapy.
The development of checkpoint immunotherapies
improved clinical outcomes for patients with melanoma,
lung cancer and other malignancies. Yet for patients with
breast cancer, the second-leading cancer diagnosis among
women in the United States, these therapies provided
limited benefit.
Seeking to optimize clinical benefit for these patients,
Dr. Fox and his team examined whether the timing and
sequence of immunotherapy combinations affect clinical
outcomes. Their findings reveal significant insights,
which may improve the administration of cancer care
and immunotherapy clinical trials for patients with breast
cancer and other malignancies.

Bernard A. Fox, Ph.D., member and Harder Family Endowed Chair for Cancer Research,
Molecular and Tumor Immunology Laboratory

IMMUNOTHERAPY SEQUENCING
In a preclinical breast cancer model, his lab tested the
combination of two immune-modulating antibodies –
anti-PD-1 and anti-OX40 – compared to both therapies
given alone, which yielded unexpected findings. “We
were really surprised to see the simultaneous combination
of anti-OX40 and anti-PD-1 was less effective than either
therapy given alone,” said Dr. Fox. Equally surprising,
when anti-OX40 was given prior to anti-PD-1, but not
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in the reverse order, the sequential combination showed
the greatest clinical benefit of all their study models.
“The timing and sequence of the two agents had
a profound impact on their biological effects,” said
Dr. Fox. Anti-OX40 administered prior to antiPD-1 provided an apparent 30 percent cure rate in a
previously incurable model. These results, published
in Clinical Cancer Research, drew the attention of the
National Cancer Institute and the American Association
for Cancer Research. In articles featuring Dr. Fox’s
study, both organizations noted the need for a better
understanding of the biological mechanisms of action
when immunotherapies are combined in clinical trials.

By examining tissue biomarkers
in an individual patient’s tumor,
doctors may be able to make
better predictions of which
immunotherapies will generate
the most effective anti-cancer
immune response.
“Our research demonstrates the need for
well-controlled clinical trials of immunotherapy
combinations. I think that is how we are going to make
greater progress against cancer,” said Dr. Fox.
IMMUNE PROFILING
To evade detection and elimination by the immune
system, tumors employ multiple mechanisms of immune
escape. By analyzing patients’ immune profiles and their
tumors, such as the type and frequency of tumor-killing
T cells that infiltrate tumors and how tumors escape
detection, clinicians may gain valuable insights to guide
their treatment strategies.

As an investigator of the global Immunoscore study,
an independent prognostic tool shown to predict
recurrence and survival in patients with colorectal cancer,
Dr. Fox and his lab are at the forefront of developing
prognostic biomarkers for cancer. In collaboration with
his Immunoscore co-investigator Carlo B. Bifulco, M.D.,
member and director, Translational Molecular Pathology,
along with R. Bryan Bell, M.D., D.D.S., FACS, and
Rom S. Leidner, M.D., assistant members and
co-directors, Providence Head and Neck Cancer
Program, Dr. Fox assessed the immune profiles of
119 patients with HPV-negative oral squamous cell
carcinoma, a type of head and neck cancer.
Using multispectral imaging and objective assessment
tools, they performed the first comprehensive immune
profiling study of patients with this disease. Evaluation
of six biomarkers revealed a positive correlation between
patient survival and increased tumor-infiltrating
T cells, with a concurrent absence of immune
suppression mechanisms.
“By examining tissue biomarkers in an individual
patient’s tumor, doctors may be able to make better
predictions of which immunotherapies will generate the
most effective anti-cancer immune response,” said Dr.
Fox. “Our study suggests that the evaluation of multiple
parameters is necessary to identify patients in need of
more aggressive treatment strategies.”
Dr. Fox presented results of the study at a joint
workshop of the Food and Drug Administration and
the American Association for Cancer Research. His lab
is collaborating with colleagues around the world to
improve technologies and assessment techniques needed
for the development of validated biomarkers to aid
clinicians in real-time decision-making.

PUBLICATIONS:
Bauman JE et al: Immunotherapy of head and neck
cancer: emerging clinical trials from a National Cancer
Institute Head and Neck Cancer Steering Committee
planning meeting. Cancer. 2017; 123(7):1259-1271.
PMID: 27906454.
Bell RB et al: Relationships matter in oral cancer: will
single-stain immunohistochemistry become irrelevant
in the age of multispectral imaging? Oral Surgery
Oral Medicine Oral Pathology Oral Radiology. 2017;
124(6):517-518. PMID: 29169510.
Bethmann D et al: Immunoprofiling as a predictor of
patient’s response to cancer therapy – promises and
challenges. Current Opinions in Immunology. 2017;
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Feng Z et al: Multiparametric immune profiling in
HPV- oral squamous cell cancer. JCI Insight. 2017;
2(14):e93652. PMID: 28724788.
Gulley JL et al: Immunotherapy biomarkers 2016:
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Cancer. 2017; 5(1):29. PMID: 28653584.
Messenheimer DJ et al: Timing of PD-1 blockade
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with anti-OX40. Clinical Cancer Research. 2017;
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Journal for ImmunoTherapy of Cancer. 2017; 5(1):103.
PMID: 29258618.
Seven of 12 publications shown.
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LABORATORY RESEARCH: Tumor Microenvironment Laboratory

Tumor Microenvironment
Laboratory
As a radiation oncologist and immunologist,
Kristina H. Young, M.D., Ph.D., is studying how
immunotherapy can remodel patients’ tumor
environments to increase the effectiveness of
conventional cancer therapies.
For patients with colorectal cancer, the most common
cancer among men and women in the United States after
breast, prostate and lung cancers, conventional cancer
therapies – chemotherapy, radiation and surgery – have
been the mainstay of treatment for decades. Nevertheless,
colorectal cancer remains the fourth-leading cause of
cancer death in this population, prompting a surge
of investigation into combining immunotherapy and
conventional therapy to improve survival. Dr. Young leads
an innovative clinical trial testing a novel immunotherapy
in combination with chemoradiation, offering hope to
patients with this lethal disease.

Kristina H. Young, M.D., Ph.D., assistant member,
Tumor Microenvironment Laboratory

TUMOR IMMUNE INFILTRATION
Studies show a correlation between patient survival and
infiltration of their tumors by cancer-killing CD8 T cells,
regulatory T cells, known as Tregs, and macrophages,
another immune cell with regulatory functions. Tumors
exhibiting little infiltration of CD8 T cells, increased
macrophage infiltration and a high ratio of Tregs to
CD8 T cells are associated with a poor tumor immune
profile, or low immune score. In patients with colorectal
cancer, low immune scores are linked to decreased overall
survival, and high scores correlate with improved survival.
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Seeking to improve prognosis for these patients,
Dr. Young studied whether modifying patients’ tumor
immune environments can improve their responses to
therapy. She tested whether inhibiting transforming
growth factor beta, or TGF-ß – a protein with important
immune signaling functions, would increase the
effectiveness of radiation therapy.
TGF-ß INHIBITION
Through its signaling pathway, TGF-ß aids in cellular
proliferation and differentiation, and the activation of
immune cells. In cancer cells, however, mutations may
alter the signaling pathway, leading to cancer growth and
a tumor environment with poor immune infiltration.
Blocking the TGF-ß pathway can disrupt these cancerpromoting forces.
“Our experiments demonstrate that pretreatment
TGF-ß blockade improved the tumor immune
environment in preclinical models, and significantly
improved the effectiveness of subsequent radiation
therapy,” said Dr. Young. “We demonstrated that this
effect was entirely dependent on CD8 T cells, and
generated long-term, tumor-specific protection.”
ONE-OF-A-KIND CLINICAL TRIAL
Armed with promising preclinical data, Dr. Young
wasted no time in offering this novel combination to
patients with colorectal cancer. By participation in her
phase II, investigator-initiated study – the first of its kind
worldwide, patients diagnosed with stage II and higher
rectal cancer who are slated for conventional therapy
may opt to receive immunotherapy as part of their
treatment regimens.
Galunisertib, a small molecule inhibitor of TGF-ß,
is administered to patients in the form of daily pills for

two weeks prior to radiation and chemotherapy, and
continued throughout their treatments.
Of 50 patients expected to participate, the first three
patients experienced a dramatic response: one patient’s
tumor disappeared completely, and the others had more
than a 75 percent decrease in tumor size, with equally
impressive responses in their lymph nodes.

Our studies demonstrate there are
significant opportunities to manipulate
the immune environment of tumors
for therapeutic gain.
The study also seeks to evaluate patients’ immune
scores as potential biomarkers to predict therapeutic
response. By monitoring patients’ immune responses
throughout treatment, and correlating changes in
their tumor immune infiltrate to imaging analysis and
treatment response, Dr. Young hopes to aid in the
development of a prognostic tool to guide treatment
decisions. In patients who respond to treatment, she
expects to see remodeling of their tumor environments
toward a more favorable immune score with increased
CD8 T cells, decreased macrophages and a low
Treg:CD8 T-cell ratio.
“Our studies demonstrate there are significant
opportunities to manipulate the immune environment
of tumors for therapeutic gain. These initial responses are
very exciting and make us hopeful that this therapy will
improve outcomes for patients with this deadly disease,”
said Dr. Young.
Preliminary results were presented by her lab at the
2017 annual meetings of the American Society for
Radiation Oncology and the Society for Immunotherapy
of Cancer, among other conferences.

PUBLICATIONS:
Baird JR, Feng Z, Xiao HD, Friedman D, Cottam
B, Fox BA, Kramer G, Leidner RS, Bell RB, Young
KH, Crittenden MR, Gough MJ: STING expression
and response to treatment with STING ligands in
premalignant and malignant disease. PLoS One. 2017;
12(11):e0187532. PMID: 29135982.
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Breast Cancer
Together, Alison K. Conlin, M.D., MPH, and
David B. Page, M.D., oversee a vast portfolio
of clinical trials and therapies for patients
with breast cancer. From early-stage disease
to metastatic and triple-negative breast
cancer, they seek to improve quality of life and
survival for patients with this pervasive cancer.
In addition to being the most common cancer among
women in the United States after skin cancer, breast
cancer is also one of the deadliest, second only to deaths
from lung cancer. By conducting novel studies, Drs.
Conlin and Page hope to improve breast cancer care so
that more patients will benefit.

David B. Page, M.D., assistant member, Breast Cancer Immunotherapy, and
Alison K. Conlin, M.D., MPH, associate member and medical director,
Providence Breast Cancer Medical Program and High-Risk Breast Clinic

PREOPERATIVE IRX-2
Dr. Page devised a phase I clinical trial testing an
experimental immunotherapy in women and men
diagnosed with stage I-III breast cancer. The study
includes patients with triple-negative breast cancer, a
type of breast cancer in which three common receptors –
estrogen, progesterone and HER2 – are absent, making
it one of the most difficult forms to treat. He examined
whether IRX-2, an immune-boosting cytokine therapy
shown to shrink tumors in other cancers, improves
clinical responses when administered prior to surgery.
For 10 consecutive days, patients received local
injections of IRX-2 as preoperative therapy. A mild
chemotherapy was also administered prior to surgery to
deplete T regulatory cells, a type of immune-suppressing
cell. Tumor and blood samples were assessed for the
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presence of immune activation markers and tumorinfiltrating lymphocytes, or TILs – signs that IRX-2
treatment boosted patients’ immune responses. TILs are
associated with improved survival in patients with earlystage breast cancer.
“We found that IRX-2 was well-tolerated with
preliminary evidence of increased TIL recruitment,
peripheral lymphocyte activation and T-regulatory
depletion,” said Dr. Page. He presented early results of
the trial, which is ongoing, at the 2017 annual meeting
of the Society for Immunotherapy of Cancer.
HER2CLIMB
Roughly 20 percent of breast cancers test positive for
HER2, a protein known to promote cancer growth.
HER2-positive tumors can spread more quickly and are
less sensitive to hormone therapy than other types of
breast cancer.

These women, many whose cancers
had spread to the brain, benefited
from extended disease survival for a
significant period of time.
Therapies that target the HER2 protein can be
effective, particularly in early-stage disease. For patients
with metastatic cancer, however, five-year survival
outcomes are a dismal 22 percent. “When treating
metastatic breast cancer, often our goal is to halt its
growth and keep it from traveling to new places in the
body,” said Dr. Conlin. Brain metastases are common in
patients with advanced disease.
An investigator on the global HER2CLIMB
study, Dr. Conlin is evaluating whether tucatinib, an

experimental inhibitor of HER2, might improve survival
in patients with HER2-positive breast cancer. The phase
I/II study tests tucatinib in combination with targeted
therapies in patients with locally advanced or metastatic
HER2-positive breast cancer.
The study is ongoing, and preliminary results were
presented at the European Society for Medical Oncology
2017 Congress and the 2017 San Antonio Breast Cancer
Symposium. “Our findings demonstrate 20 percent of
patients treated with tucatinib combinations for advanced
breast cancer were free of progressing disease at 16 months
or more,” said Dr. Conlin. “These women, many whose
cancers had spread to the brain, benefited from extended
disease survival for a significant period of time.”

PUBLICATIONS:

CANCER-RELATED FATIGUE
Designated a high-priority area of research by the
National Cancer Institute, cancer-related fatigue, or
CRF, is a common complaint among breast cancer
patients, affecting quality of life and treatment adherence.
Dr. Conlin engaged in a nationwide, longitudinal study
comparing CRF in women with breast cancer to women
without cancer. “We found that breast cancer survivors
experience significantly more CRF prior to and after
chemotherapy compared to healthy patients,” said
Dr. Conlin.
Study results drew the attention of the American
Society of Clinical Oncology, which published the
findings and an accompanying editorial in its Journal
of Clinical Oncology. The society, whose annual report
noted CRF management among the most important
patient care advances of the year, also selected the study
for presentation at its 2017 annual meeting.
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Cytokine and Adoptive
Immunotherapy
An expert in cytokine and adoptive
immunotherapy, Brendan D. Curti, M.D., is
engaged in numerous investigator-initiated
and industry-sponsored clinical trials to
improve survival of patients with cancer.
Cytokines are proteins with cell-signaling functions
important in regulating immune responses, and are
instrumental in rejecting cancers. Interleukin-2, known
as IL-2, is a type of immune-boosting cytokine proven
to be effective when administered in high doses to
patients with melanoma and renal cell carcinoma, a type
of kidney cancer. Dr. Curti oversees one of the busiest
programs in the country for high-dose IL-2, and the
largest program on the West Coast.

Brendan D. Curti, M.D., member and director, Cytokine and Adoptive Immunotherapy
Program, Genitourinary Oncology Research and Providence Melanoma Program

PROCLAIM STUDY
Like other immunotherapies, IL-2 can induce
unexpected complications, such as immune-related
adverse events – or irAEs, ranging from reversible
symptoms to potentially life-threatening side effects.
Common irAEs include thyroid dysfunction and vitiligo,
a condition causing the loss of skin color. While some
studies suggest a positive association between irAEs and
patient survival, consensus among medical professionals
is lacking.
Seeking to provide contemporary assessment of the
relationship between clinical benefit and irAEs from
IL-2, Dr. Curti is the lead author of a nationwide,
multicenter observational study, known as PROCLAIM,
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to evaluate the treatment patterns and clinical responses
of high-dose IL-2 in patients with metastatic renal cell
carcinoma and metastatic melanoma. Of the 1,535
patients enrolled to the study from 2008 to 2016, 130
patients experienced irAEs. As reported in the Journal for
ImmunoTherapy of Cancer, the development of irAEs
related to IL-2 is associated with significantly improved
overall survival compared to patients with no irAEs.
“Our study supports the association of immune
activation from immunotherapy with better patient
outcome,” said Dr. Curti. “Although it would be ideal
for patients to have immunotherapy with no side effects,
this work supports that clinical benefit is linked with side
effects related to the immune activity of IL-2.”
PIVOT-02 STUDY
Dr. Curti is investigating another cytokine showing
promise when given with checkpoint immunotherapy in
patients with advanced solid cancers. As a lead investigator
of the phase I/II multicenter clinical trial known as
PIVOT-02, he is studying NKTR-214, a chemically
modified form of IL-2, given in combination with
nivolumab, an anti-PD-1 checkpoint immunotherapy
approved for treating a variety of cancers.
Preclinical studies indicate NKTR-214 boosts the
proliferation of cancer-killing CD8 T cells within
the tumor microenvironment without increasing the
activity of immune-suppressing T regulatory cells.
These properties are due to its pegylation, a chemical
modification which alters the receptor binding of
IL-2. NKTR-214 also enhances expression of PD1, an immune checkpoint protein responsible for
regulating immune responses. Through inhibiting
PD-1, nivolumab increases the life span and activity of
T cells, which can facilitate the destruction of cancer.

Investigators hypothesized that the complementary
mechanisms of action of these two immunotherapies
would result in greater overall survival than seen in either
therapy alone.
When given as first- or second-line therapy to 38
patients with multiple tumor types, responses were
observed in 46 percent of patients with renal cell
carcinoma, 64 percent with melanoma, and 75 percent
with non-small cell lung cancer. Patients with bladder
cancer and triple-negative breast cancer are also eligible
to enroll.

Our study supports the association of
immune activation from immunotherapy
with better patient outcome.
“By increasing the proliferation of CD8 T cells in
the tumor and increasing PD-1 expression, NKTR214 demonstrated a potentially synergistic mechanism
with anti-PD-1 therapy, confirming observations from
the preclinical studies,” said Dr. Curti. “These data
demonstrate that NKTR-214 and nivolumab are welltolerated in the outpatient setting with encouraging
response rates, and warrant further investigation.”
Investigators aim to enroll 350 patients across 13
cohorts in the phase II study, and a second study arm
was added to test NKTR-214 in combination with
nivolumab and ipilimumab, another checkpoint
immunotherapy approved for several cancers. The study
was selected for oral abstract presentation at the 2017
annual meeting of the Society for Immunotherapy of
Cancer, and presented at other major conferences in the
United States and Europe.

PUBLICATIONS:
Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman
HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N,
Morse MA, Wong MKK, Dutcher JP: Improved survival
and tumor control with interleukin-2 is associated
with the development of immune-related adverse
events: data from the PROCLAIM registry. Journal for
ImmunoTherapy of Cancer. 2017; 5(1):102. PMID:
29254506.
Faries MB, Curti BD. Melanoma. In: Bell RB, Fernandes
RP, Andersen PE, eds. Oral, Head and Neck Oncology
and Reconstructive Surgery. China: Elsevier;
2017:877-91.
Sckisel GD, Mirsoian A, Minnar CM, Crittenden M,
Curti B, Chen JQ, Blazar BR, Borowsky AD, Monjazeb
AM, Murphy WJ: Differential phenotypes of memory
CD4 and CD8 T cells in the spleen and peripheral
tissues following immunostimulatory therapy. Journal
for ImmunoTherapy of Cancer. 2017; 5(33). PMID:
28428882.
Siefker-Radtke A, Curti B: Immunotherapy in metastatic
urothelial carcinoma: focus on immune checkpoint
inhibition. Nature Reviews Urology. 2017; 15(2):112124. PMID: 29205200.

24

LABORATORY
CLINICAL
RESEARCH:
RESEARCH:
Gastrointestinal
Antitumor T-cell
Cancer
Response Laboratory

Gastrointestinal Cancer
From novel surgical techniques to innovative
immunotherapy studies, Todd S. Crocenzi,
M.D., and Pippa H. Newell, M.D., seek
to improve outcomes for patients with
gastrointestinal cancers.

Pippa H. Newell, M.D., assistant member and medical director, Providence
Liver Cancer Clinic, and Todd S. Crocenzi, M.D., associate member and director,
Gastrointestinal Oncology Research

MISMATCH-REPAIR BREAKTHROUGH
In collaboration with researchers at Johns Hopkins
University, Dr. Crocenzi demonstrated that patients with
advanced colorectal cancer were responsive to anti-PD-1
checkpoint immunotherapy when their tumors were
defective in repairing mismatched DNA.
This deficiency, known as mismatch repair – or
MMR, occurs when cells lack the ability to correct errors
in DNA replication. When left uncorrected, these errors
– known as mutations – accumulate in vast quantities,
acting as targets of anti-tumor immune responses.
A phase II study by Dr. Crocenzi and colleagues
revealed that pembrolizumab, an anti-PD-1 checkpoint
inhibitor approved for numerous cancers, was effective
in mediating cancer regression in patients with MMRdeficient colorectal cancers bearing high numbers
of mutations.
While only a minority of patients with colorectal
cancer have MMR-deficient tumors, the investigators
hypothesized that other patients who shared the
deficiency would also benefit from anti-PD-1 therapy
regardless of where their tumors originated. They tested
this premise by expanding their study to include 12 types
of advanced MMR-deficient cancer, such as pancreas,
prostate, uterine and bone cancers.
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As reported in the journal Science, their premise was
correct: 66 of 86 patients enrolled to the trial saw their
tumors shrink or stabilize. In 18 of those responders,
their tumors vanished completely. “Based on these
responses, our estimates of overall survival at one and two
years were 76 percent and 64 percent, which is markedly
higher than expected due to the advanced state of disease
in these patients,” said Dr. Crocenzi.
The results drew national headlines, including an
article in The New York Times, and spurred the Food
and Drug Administration to accelerate approval of
pembrolizumab for MMR-deficient cancers, marking
the first instance of a cancer drug approval based on a
shared genetic profile rather than cancer type or site
of origination.

These results tie immunity, cancer
genetics and therapeutics together in
a manner that will likely establish a
new standard of care.
Testing for MMR deficiency is widely available, and
the investigators estimate up to 60,000 cancer patients
annually could benefit. “These results tie immunity,
cancer genetics and therapeutics together in a manner
that will likely establish a new standard of care,” said
Dr. Crocenzi.
HCC APPROVAL
For patients with advanced hepatocellular carcinoma, or
HCC – the most common type of primary liver cancer,
outcomes remain poor, limited by a lack of treatment
options. Dr. Crocenzi and other collaborators conducted
a phase I/II study of nivolumab, another anti-PD-1
checkpoint inhibitor, in patients with HCC.

In an article for The Lancet, they reported a favorable
safety profile and early evidence of clinical activity. Dr.
Crocenzi presented preliminary results of the study at
the 2017 annual meeting of the American Society of
Clinical Oncology, where he noted durable responses
were observed with long-term survival. Soon after, the
FDA granted nivolumab accelerated approval for patients
with advanced HCC whose cancers progressed following
systemic therapy – the first immunotherapy approved for
this population.
FRS VALIDATION
As a liver and pancreas surgeon, Dr. Newell is engaged
in studies to improve surgical techniques and patient
outcomes. With colleagues at Providence Cancer
Institute, she evaluated a risk assessment tool to predict
the postsurgical onset of pancreatic fistula following
pancreaticoduodenectomy – the most common
operation to treat pancreatic cancer – also known
as a Whipple procedure. Consisting of abnormal
communication between the pancreas and surrounding
organs, pancreatic fistula is the most common
complication arising from this procedure, and can be
life-threatening.
They conducted a prospective assessment of four
centers in the United States and Canada, evaluating
the use of Fistula Risk Score, or FRS, in a total of
444 patients undergoing the operation. As reported
in the journal HPB, their findings strengthened the
clinical validity of FRS. “We can now predict the risk
of pancreatic fistula intraoperatively with satisfactory
accuracy,” said Dr. Newell.
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Genomics
An expert in translational molecular pathology,
Carlo B. Bifulco, M.D., is engaged in numerous
studies to characterize the tumor immune
environment through genome sequencing and
advanced immunohistochemistry and image
analysis techniques.

Carlo B. Bifulco, M.D., member and director, Translational Molecular Pathology,
and medical director, Molecular Genomics

PERSONALIZED MEDICINE
In the past decade, advances in genome sequencing have
enabled real-time, high-throughput DNA sequencing
– also known as next-generation sequencing, or
NGS. As the costs of NGS continue to fall, access by
physicians and patients to this powerful diagnostic and
predictive tool has increased, and ushered in a new era of
personalized medicine.
As medical director of Molecular Genomics, Dr.
Bifulco leads the Oregon hub of Providence Personalized
Medicine Program, the systemwide NGS program of
Providence St. Joseph Health. The program is available to
test samples from patients with solid tumors and blood
cancers who are receiving standard-of-care therapies
or participating in clinical trials. Tests include targeted
panels, whole exome and RNA sequencing.
Dr. Bifulco is aided by computational and systems
biologist Brady Bernard, Ph.D., genomic scientist
Brian Piening, Ph.D., and a team of bioinformaticists.
They use state-of-the-art equipment, custom-built
bioinformatics pipelines and sophisticated computational
models to identify genetic mutations in patients’ tumors.
Some mutations may be targeted therapeutically, lending
valuable insight to clinicians for the development of
individualized treatment plans based on patients’ unique
genetic profiles.
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PRECISION IMMUNOTHERAPY
Through the integration of genomics and immunotherapy,
it is now possible to identify neoantigens, proteins encoded
by tumor-specific mutated genes, to serve as targets of
immunotherapy.

We hope the knowledge acquired
through genome sequencing will lead
us to cures for cancer.
With extensive experience in the development of
NGS assays for immune profiling, Dr. Bifulco’s team
is at the forefront of harnessing the power of genomics
for precision immunotherapy. “We developed a
comprehensive solid tumor NGS panel with the dual
purpose of detecting clinically relevant, targetable
regions of the genome and identifying neoantigens for
immunotherapy applications,” said Dr. Bifulco.
They were invited to give presentations highlighting
their expertise in NGS for immunotherapy at the
2017 annual meeting of the Association for Molecular
Pathology.
TRI-SEQ NGS STUDY
In collaboration with Rom S. Leidner, M.D., assistant
member and co-director, Providence Head and Neck
Cancer Program, and other investigators, Dr. Bifulco leads
a clinical trial to study the effects of patients’ genomes
on their responses to immunotherapy. The study, known
as Tri-Seq NGS, aims to characterize neoantigens by
harnessing three complementary levels of genetic data:
tandem DNA and RNA sequencing from tumor samples,
and DNA sequencing from normal tissue. Dr. Bifulco’s
team uses novel computational approaches to mine for

molecular differences between tumor and normal cells
that can be targeted by immunotherapies.
The study supports essential functions of the
Antitumor T-cell Response Laboratory led by Assistant
Member Eric Tran, Ph.D. Dr. Tran is an expert in
adoptive cell therapy, a promising approach to curing
cancer by amplifying patients’ tumor-killing T cells
in the lab and giving them back to patients in greater
quantities. Dr. Tran will partner with Dr. Bifulco and
other clinicians to create highly personalized, genomeguided immunotherapies.
Tri-Seq NGS is open to patients with head, neck,
pancreas and other types of cancer, and Dr. Tran plans
to begin clinical trials as early as 2019. “We hope the
knowledge acquired through genome sequencing will
lead us to cures for cancer,” said Dr. Bifulco.
IMMUNOSCORE
Together with Bernard A. Fox, Ph.D., member
and Harder Family Chair, Molecular and Tumor
Immunology Laboratory, Dr. Bifulco serves on a global
study supported by the Society for Immunotherapy
of Cancer to incorporate the immune contexture
into cancer staging and classification. By analyzing
the immune contextures of more than 3,000 cancer
patients, investigators have developed a new scoring
system, known as Immunoscore, to help predict patient
outcomes to therapy.
An article in the Journal of Translational Medicine
co-written by Dr. Bifulco suggests Immunoscore may
become a new component of cancer classification based
on immune parameters. “This will represent the first
standardized immune-based assay for classifying cancer
in the era of immunotherapy,” said Dr. Bifulco.
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Head and Neck Cancer
As co-directors of Providence Head and Neck
Cancer Program, Rom S. Leidner, M.D., and
R. Bryan Bell, M.D., D.D.S., FACS, oversee one
of the largest immunotherapy clinical trial
portfolios for head and neck cancer on the
West Coast.
Head and neck cancer accounts for nearly 50,000 new
cancer diagnoses in the United States annually, and is
the sixth most common cancer worldwide. While fiveyear survival rates for early-stage disease are 83 percent,
only 38 percent of patients with advanced cancers
survive beyond five years. Drs. Bell and Leidner lead
innovative immunotherapy studies to improve survival
for these patients.

Rom S. Leidner, M.D., assistant member and co-director, Providence Head and
Neck Cancer Program, and R. Bryan Bell, M.D., D.D.S., FACS, assistant member
and medical director, Providence Head and Neck Cancer Program and Clinic

ANTI-OX40 PHASE I STUDY
Head and neck squamous cell carcinomas, or HNSCC,
are known to produce suppressive factors which can
impair anti-cancer immune responses. Drs. Bell and
Leidner hypothesized that anti-OX40, an experimental
immune-stimulating antibody developed at the Earle A.
Chiles Research Institute, may enhance the activation of
tumor-killing T cells when administered before surgery.
They are testing this concept in an investigator-initiated,
phase I clinical trial to evaluate the effectiveness and
safety of anti-OX40 given before conventional surgical
resection in patients with locally advanced HNSCC.
Beginning two weeks before surgery, patients received
intravenous infusion of anti-OX40. Tumor and blood
samples were obtained prior to anti-OX40 treatment and
at the time of surgery to assess the effects of anti-OX40
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on tumor-infiltrating immune cell populations and other
immunological functions. The study is the most in-depth
analysis of immune response conducted in a surgical trial,
representing a pioneering collaboration with their clinical
and scientific colleagues.
Dr. Bell presented preliminary results at the 2017
International Conference on Oral and Maxillofacial
Surgery. “We found that preoperative anti-OX40 is
feasible and safe in patients with HNSCC, and results
in the activation and proliferation of T-cell populations
in both the tumor microenvironment and in circulation,”
said Dr. Bell. Results from the ongoing study were
also presented at the 2017 Head and Neck Cancer
Conference, a joint meeting of the American Association
for Cancer Research and the American Head and
Neck Society.
ADOPTIVE CELL THERAPY
Dr. Leidner is the first investigator in Oregon to
offer patients with HNSCC adoptive cell therapy, or
ACT. Celebrated as the Advance of the Year by the
American Society of Clinical Oncology, ACT is a highly
personalized immunotherapy in which patients’ tumorkilling T cells are extracted, reinforced in a lab and
reinfused in greater quantities.
Studies show the clinical benefit of ACT in cancers
that bear many genetic mutations, or are virally
associated. In collaboration with Brendan D. Curti,
M.D., member and director, Cytokine and Adoptive
Immunotherapy Program, Dr. Leidner is testing the
safety and effectiveness of ACT in HNSCC, a cancer
associated with human papillomavirus and a high
number of mutations.
In the phase II, multicenter study, patients receive
reinfusion of their enhanced tumor-infiltrating

lymphocytes, followed by interleukin-2, another
immunotherapy shown to boost anti-cancer immune
responses. The study is ongoing, and preliminary results
were presented at the 2017 annual meeting of the Society
for Immunotherapy of Cancer.
LIRILUMAB GLOBAL STUDY
In another phase I/II trial, Dr. Leidner is evaluating a
combination of two immunotherapies for patients with
advanced HNSCC and other solid tumors.
Natural killer cells, or NK cells, play a critical
role in immune surveillance and controlling tumor
growth. Activation of NK cells is regulated in part
by killer-cell immunoglobulin-like receptors, known
as KIRs. Blocking KIR function may facilitate anticancer immune responses, and synergize with other
immunotherapies. To test this premise, Dr. Leidner
is leading the global investigation of lirilumab, an
experimental NK-cell inhibitor, in combination with
nivolumab, an immune checkpoint inhibitor approved
for several cancers.

We observed encouraging
responses that were deep and
durable in some patients.
The study was presented at the 2017 International
Congress on Targeted Anticancer Therapies, where
preliminary results demonstrated clinical benefit. Of
41 patients with HNSCC, 52 percent saw their tumors
shrink or stabilize in response to therapy. “We observed
encouraging responses that were deep and durable in
some patients,” said Dr. Leidner. “These findings warrant
further study of this novel combination.”
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Hematologic
Malignancies
John E. Godwin, M.D., MS, is investigating
novel immunotherapies for patients with
hematologic malignancies, also known as
blood cancers.
Acute myeloid leukemia, or AML – a type of cancer
arising from abnormal development of blood cells in
the bone marrow, is a common type of leukemia in the
United States; approximately 19,500 people are newly
diagnosed each year. An acute disease that can progress
rapidly if untreated, it is the most deadly leukemia
among adults, with less than 28 percent of adult AML
patients surviving beyond five years.
Also resulting from abnormal bone marrow cells,
myelodysplastic syndromes, or MDS, are hematologic
conditions marked by low numbers of blood cells. An
estimated 14,000 new diagnoses of MDS occur annually,
most of them in older adults.
Considered a type of blood cancer, patients with
MDS are assessed for their risk of developing AML. The
World Health Organization classifies MDS by five risk
groups ranging from very low risk to very high risk. For
patients in the intermediate risk group, an estimated 33
percent will develop AML within five years; in very highrisk patients, the chance of developing AML within five
years jumps to 84 percent.

John E. Godwin, M.D., MS, member and program leader, Hematologic Malignancies

FIRST-IN-HUMAN STUDY
Dr. Godwin is among a global cohort of investigators
testing a new immunotherapy in a phase I, first-in-
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human study of adult patients with AML and MDS.
Flotetuzumab, a bispecific antibody administered by
intravenous infusion, is capable of binding to two
distinct cell-surface molecules simultaneously. Through
dual recognition of CD123, a molecule overexpressed
in hematologic malignancies like AML and MDS, and
CD3, another molecule known to stimulate the activity
of cancer-killing T cells, flotetuzumab can redirect T cells
toward their malignant targets.

We have seen leukemia patients
who are unresponsive to other
therapies go into complete
remission with this immunotherapy.
While immunotherapy is effective in other cancers
such as B-cell hematologic malignancies, AML has
remained resistant to antibody-based therapies due to
a lack of appropriate molecular targets. Yet for more
than 90 percent of patients with AML, CD123 is
highly expressed; in patients with MDS, the molecule
is prevalent in more than 50 percent of patients. With
evidence of anti-leukemic activity in preclinical studies
of flotetuzumab, study investigators hoped the bispecific
therapy would bring clinical benefit to patients with
these formidable malignancies.
The study, which is ongoing, is testing the safety and
effectiveness of flotetuzumab in patients with refractory
or relapsed AML, or intermediate to high-risk MDS. Of
13 sites participating worldwide, five are in the United
States, and Dr. Godwin is the only investigator on the
West Coast enrolling patients to the study.
Early results were presented at major conferences
across the United States and Europe. At the 2017 annual

meeting of the American Society of Hematology, Dr.
Godwin was invited to present preliminary data in an
oral abstract session. Of 57 patients participating in the
trial, a minority were enrolled to a dose expansion cohort
to determine the maximum tolerated dose. Among this
group, 75 percent demonstrated anti-leukemic activity,
and two patients experienced a complete response.
“We have seen leukemia patients who are
unresponsive to other therapies go into complete
remission with this immunotherapy,” said Dr. Godwin.
“These early study results are encouraging, and warrant
further investigation.”
CHECKPOINT COMBINATION
In another abstract selected for presentation by the
American Society of Hematology, Dr. Godwin, together
with Bernard A. Fox, Ph.D., member and Harder
Family Chair, Molecular and Tumor Immunology
Laboratory, and Carlo B. Bifulco, M.D., member
and director, Translational Molecular Pathology, and
other investigators, reported translational results of
the flotetuzumab study which support the rationale
for its combination with anti-PD-1 checkpoint
immunotherapy.
Through advanced multispectral immunohistochemistry analysis, Dr. Godwin and colleagues
assessed malignant and normal tissue samples from
patients in the study. They observed synergistic anticancer activity in AML treated with flotetuzumab and
an anti-PD-1 checkpoint inhibitor. “These data suggest
that combination with anti-PD-1 therapy may enhance
the therapeutic effects of flotetuzumab in patients with
refractory or relapsed AML,” said Dr. Godwin.
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Melanoma
As experts in the clinical development of
immunotherapy for melanoma, Brendan D.
Curti, M.D., and Walter J. Urba, M.D., Ph.D.,
investigate combinations of experimental
treatments and standard-of-care therapies
to improve patient survival.

Brendan D. Curti, M.D., member and director, Cytokine and Adoptive Immunotherapy
Program, Genitourinary Oncology Research and Providence Melanoma Program, and
Walter J. Urba, M.D., Ph.D., member, director and endowed chair of Cancer Research

MITCI STUDY
Dr. Curti leads a phase I, investigator-initiated clinical
trial of CVA21, an oncolytic and immunotherapeutic
strain of coxsackievirus A21, in combination with
standard-of-care ipilimumab, an anti-CTLA-4
immune checkpoint inhibitor, in patients with
advanced melanoma.
The study, known as Melanoma Intra-Tumoral
Cavatak and Ipilimumab, or MITCI, is a collaboration
between Providence Health & Services and the
pharmaceutical sponsor. Patients receive injections
of CVA21 in their melanoma lesions, followed by
intravenous ipilimumab. A total of 60 patients are
expected to participate at 10 centers across the country.
A novel, non-genetically modified form of a common
cold virus, CVA21 targets a protein called ICAM that
is highly expressed on the surfaces of many cancer cells.
Once CVA21 attaches to ICAM, it can infect and kill
cancer cells. In preclinical studies, the death of cancer
cells induced by CVA21 primed the immune system
to recognize and destroy malignancies, suggesting a
potential synergy when it is combined with checkpoint
inhibitors and other immunotherapies.
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In recent years, the number of treatments for
patients with advanced melanoma has increased with
the development of immune checkpoint inhibitors.
However, not all patients respond to these therapies,
and some patients who respond initially develop disease
progression later. “These patients have few treatment
options and a poor outlook,” said Dr. Curti.
At the 2017 annual meeting of the American
Association for Cancer Research, Dr. Curti presented
early results, reporting better responses in patients who
received the combination compared to patients who
received either therapy given alone in prior studies. “A
significant number of patients experienced regression of
their cancers,” said Dr. Curti. “The CVA21-ipilimumab
combination may represent a valuable treatment option
for an unmet need in patients with advanced melanoma,”
said Dr. Curti.
CHECKPOINT-INDUCED TUMOR EVOLUTION
In another multicenter phase I study, Dr. Urba
and colleagues evaluated the mechanisms by which
checkpoint inhibition modulates tumor evolution in
patients with advanced melanoma.
As reported in the journal Cell, they observed changes
in patients’ tumors in response to treatment with
nivolumab, an anti-PD-1 checkpoint inhibitor. Through
DNA, RNA and T-cell receptor sequencing, they found
the tumor mutation burden – the number of mutations
within a tumor genome – was reduced in responding
tumors. A high tumor mutation burden is associated
with an increase in neoantigens – proteins encoded by
tumor-specific mutated genes which may serve as targets
of checkpoint inhibitors.

They also observed an increase in immune cell
infiltration of responding tumors, and the expansion
of specific T-cell clones. “T-cell clonal expansion
accompanied by the loss of neoantigens suggests the
development of an effective immune response,” said
Dr. Urba. “These data have important implications for
understanding the mechanisms of action of checkpoint
inhibitors and for the design of future clinical trials.”
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ADOPTIVE CELL THERAPY
In collaboration with Loyola University, Dr. Curti
engaged in a phase I study of adoptive cell therapy, or
ACT, in patients with metastatic melanoma. Celebrated
as the Advance of the Year by the American Society
of Clinical Oncology, ACT harnesses the ability of
the immune system to eliminate cancer through the
collection, amplification and reinfusion of patients’
tumor-killing T cells.
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A significant number of patients
experienced regression of their cancers.
The investigators sought to enhance the tumor-killing
potency of patients’ T cells through T-cell engineering. In
the ongoing study, they tested the safety and effectiveness
of T cells endowed with a new receptor capable of
recognizing tyrosinase, an enzyme present in most
melanoma cells. “The future of ACT will involve more
sophisticated T-cell engineering,” said Dr. Curti. “We are
at the forefront of these efforts.” Dr. Curti will continue
his investigation of novel ACT in partnership with
Eric Tran, Ph.D., assistant member, Antitumor T-cell
Response Laboratory, whose lab is focused on identifying
neoantigens with potential for targeting by ACT.

Curti B, Daniels GA, McDermott DF, Clark JI, Kaufman
HL, Logan TF, Singh J, Kaur M, Luna TL, Gregory N,
Morse MA, Wong MKK, Dutcher JP: Improved survival
and tumor control with interleukin-2 is associated
with the development of immune-related adverse
events: data from the PROCLAIM registry. Journal for
ImmunoTherapy of Cancer. 2017; 5(1):102. PMID:
29254506.

Riaz N, Havel JJ, Makarov V, Desrichard A, Urba WJ,
Sims JS, Hodi FS, Martin-Algarra S, Mandal R, Sharfman
WH, Bhatia S, Hwu WJ, Gajewski TF, Slingluff CL, Jr.,
Chowell D, Kendall SM, Chang H, Shah R, Kuo F, Morris
LGT, Sidhom JW, Schneck JP, Horak CE, Weinhold N,
Chan TA: Tumor and microenvironment evolution
during immunotherapy with nivolumab. Cell. 2017;
171(4):934-949.e15. PMID: 29033130.
Sckisel GD, Mirsoian A, Minnar CM, Crittenden M,
Curti B, Chen JQ, Blazar BR, Borowsky AD, Monjazeb
AM, Murphy WJ: Differential phenotypes of memory
CD4 and CD8 T cells in the spleen and peripheral
tissues following immunostimulatory therapy. Journal
for ImmunoTherapy of Cancer. 2017; 5(33). PMID:
28428882.
Tran E, Longo DL, Urba WJ. A milestone for CAR T
cells. The New England Journal of Medicine. 2017;
377(26):2593-6. PMID: 29226781.
Five of 10 publications shown.
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Phase I Studies and
Lung Cancer
Rachel E. Sanborn, M.D., oversees a robust
phase I clinical trials portfolio of experimental
cancer immunotherapies, targeted therapies
and other novel agents. An expert in thoracic
cancers, she leads numerous studies to improve
outcomes for patients with lung cancer.

Rachel E. Sanborn, M.D., associate member, Phase I Clinical Trials Program,
and co-director, Providence Thoracic Oncology Program

PHASE I STUDY FOR ADVANCED CANCERS
At the 2017 annual meeting of the American Society
of Clinical Oncology, Dr. Sanborn gave an oral
abstract presentation on a phase I/II study investigating
varlilumab, an immune-stimulating antibody, in
combination with nivolumab, an anti-PD-1 checkpoint
inhibitor approved for several cancers.
Varlilumab targets and binds to CD27, a protein
found on the surfaces of T cells, activating an anticancer immune response. Investigators hypothesized the
combination of varlilumab and nivolumab could have
an additive benefit compared to the minimal response
expected if patients were given nivolumab only.
The study aims to test the safety and anti-cancer
activity of varlilumab in patients with advanced cancers
that have resisted prior therapies, including melanoma
and cancers of the colon, ovary, head and neck. Of
nearly 20 sites participating throughout the country, Dr.
Sanborn and colleagues at Providence Cancer Institute
were the first investigators to enroll patients to the study.
Reporting preliminary results, Dr. Sanborn noted
the combination was well-tolerated, and 14 of 36
patients enrolled to the study saw their tumors shrink
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or stabilize in response to therapy. These findings were
significant, given the patients’ advanced state of disease
and poor prognosis.
“Combining PD-1 inhibition with a potent T-cell
activating agent provides the opportunity to increase
the number of patients that benefit from checkpoint
immunotherapy,” said Dr. Sanborn. “While early, we have
evidence that this combination does not add toxicity and
may offer patients clinical benefit, particularly those who
are unlikely to respond to other therapies.”
Based on the favorable results, investigators will
evaluate various dose schedules to determine the optimal
treatment regimen.
LUNG CANCER VACCINE PILOT STUDY
While immune checkpoint inhibitors have improved
survival of patients with non-small cell lung cancer,
or NSCLC, the disease remains the leading cause of
cancer death worldwide. Strategies that increase immune
recognition and control of NSCLC are needed. Vaccines
present a promising approach to priming the immune
system to recognize and destroy this deadly malignancy.
In collaboration with Bernard A. Fox, Ph.D.,
member and Harder Family Chair, Molecular and
Tumor Immunology Laboratory, and Hong-Ming Hu,
Ph.D., associate member, Cancer Immunobiology
Laboratory, Dr. Sanborn conducted a pilot study to test
the safety and clinical activity of a novel cancer vaccine

Combining PD-1 inhibition with
a potent T-cell activating agent
provides the opportunity to increase
the number of patients that benefit
from checkpoint immunotherapy.

in combination with docetaxel, a standard-of-care
chemotherapy.
With support from the National Cancer Institute
and the Kuni Foundation, six patients with advanced
NSCLC received intravenous infusion of docetaxel,
followed by a cancer vaccine derived from their own
tumor cells. The autologous vaccine, known as DRibbles,
was created by Drs. Hu and Fox by isolating tumor cells
from the study patients and processing the cells into
a vaccine formulation in the laboratory. In preclinical
studies, the vaccine demonstrated both protective and
therapeutic anti-cancer immunity.
“The autologous DRibbles vaccine was safe in
the small population of patients tested,” said Dr.
Sanborn. Results were published in the Journal for
ImmunoTherapy of Cancer, and further investigation
of the DRibbles vaccine has moved forward with an offthe-shelf, or allogeneic, formulation in development for
patients with locally advanced NSCLC and other cancers.
INVESTIGATOR-INITIATED LUNG
CANCER STUDY
Another study designed for patients with advanced
NSCLC, Dr. Sanborn leads an investigator-initiated
phase I/II clinical trial of pembrolizumab, another antiPD-1 checkpoint inhibitor approved for a variety of
cancers, in combination with gemcitabine, a standard-ofcare chemotherapy.
The study was also selected for presentation by the
American Society of Clinical Oncology, where Dr.
Sanborn reported a favorable safety profile among six
patients. Approximately 16 patients are expected to
participate in the trial, which is ongoing through the
sponsorship of Providence Health & Services.

PUBLICATIONS:
Arnold SM, Chansky K, Leggas M, Thompson MA,
Villano JL, Hamm J, Sanborn RE, Weiss GJ, Chatta G,
Baggstrom MQ: Phase 1b trial of proteasome inhibitor
carfilzomib with irinotecan in lung cancer and other
irinotecan-sensitive malignancies that have progressed
on prior therapy. Investigational New Drugs. 2017;
35(5):608-615. PMID: 28204981.
Sanborn RE, Patel JD, Masters GA, Jayaram N,
Stephens A, Guarino M, Misleh J, Wu J, Hanna N: A
randomized, double-blind, phase 2 trial of platinum
therapy plus etoposide with or without concurrent
vandetanib (ZD6474) in patients with previously
untreated extensive-stage small cell lung cancer: Hoosier
Cancer Research Network LUN06-113. Cancer. 2017;
123(2):303-311. PMID: 27583688.
Sanborn RE, Ross HJ, Aung S, Acheson A, Moudgil
T, Puri S, Hilton T, Fisher B, Coffey T, Paustian C,
Neuberger M, Walker E, Hu HM, Urba WJ, Fox
BA: A pilot study of an autologous tumor-derived
autophagosome vaccine with docetaxel in patients
with stage IV non-small cell lung cancer. Journal for
ImmunoTherapy of Cancer. 2017; 5(1):103. PMID:
29258618.
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Radiation Research
As physician scientists specializing in radiation
oncology and immunotherapy, Marka R.
Crittenden, M.D., Ph.D., and Kristina H. Young,
M.D., Ph.D., seek to develop more effective
treatments for patients with cancer.
INTEGRATING RADIATION AND
IMMUNOTHERAPY
Drs. Crittenden and Young are active proponents of
incorporating radiation oncology into immunotherapy.
As members of the American Society for Radiation
Oncology and the Society for Immunotherapy of Cancer,
they were invited to attend the 2017 Immunotherapy
Workshop, a joint meeting of the societies in
collaboration with the National Cancer Institute.
Held in Washington, D.C., the workshop addressed
important topics concerning the integration of these
cancer therapies. Dr. Crittenden chaired a session
on “Rational Combinations of Radiation with
Immunotherapy,” which included colleagues from Johns
Hopkins University, the University of Pennsylvania, and
Stanford, while Dr. Young presented preliminary results of
her phase II clinical trial testing a novel immunotherapy
in combination with chemoradiation in patients with
rectal cancer. The study, which includes Dr. Crittenden as
a co-investigator, was also selected for presentation by the
two societies at their 2017 annual meetings, and at the
2017 Immuno-Oncology Young Investigators’ Forum.
Learn more about this study on Pages 4 and 18.

Marka R. Crittenden, M.D., Ph.D., associate member, Integrated Therapies Laboratory,
and director, Translational Radiation Research, and Kristina H. Young, M.D., Ph.D.,
assistant member, Tumor Microenvironment Laboratory

ACT IV GLOBAL STUDY
Glioblastoma is the most common malignant primary
brain tumor in adults. While cancers of the brain and
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nervous system account for less than two percent of
new cancer diagnoses in the United States annually,
glioblastoma is an aggressive cancer with poor prognosis:
a mere 15 months is the typical length of survival
after diagnosis.
Researchers turned to immunotherapy as a potential
approach to improve patient outcomes. An expert
in radiation and immunotherapy for patients with
glioblastoma, Dr. Crittenden engaged in a global, phase
III clinical trial testing an experimental immunotherapy
in this disease. With 165 centers in 22 countries
participating, the randomized, double-blind study
known as ACT IV is the most comprehensive of its kind.
Dr. Crittenden and colleagues evaluated the safety and
effectiveness of rindopepimut, an investigational cancer

These results underscore the importance
of well-controlled clinical trials in the
development of new treatments for cancer.
vaccine, in combination with temozolomide, a standardof-care chemotherapy, in patients with newly diagnosed
glioblastoma. Rindopepimut targets EGFRvIII, a protein
arising from a mutation of the EGFR gene, which
is expressed in up to 30 percent of glioblastomas. In
previous trials, the vaccine extended patient survival by
an average of nine months.
Of the 745 patients who enrolled, half received
rindopepimut and half received a placebo; all patients
received temozolomide. Only patients with EGFRvIIIexpressing glioblastomas were eligible, and all patients
completed surgical resection and conventional
chemoradiation prior to entering the study.
As reported in The Lancet Oncology, the investigators
found no significant difference between patients

who received the placebo and those who received the
vaccine. “While disappointing, these results underscore
the importance of well-controlled clinical trials in the
development of new treatments for cancer,” said
Dr. Crittenden. Investigators halted the study early,
yet numerous clinical trials testing various EGFRvIIItargeting strategies are ongoing in efforts to make
progress against this formidable cancer.
RADIOTHERAPY AS IMMUNOTHERAPY
In other research, Dr. Crittenden is examining how
the immunological effects of radiation therapy can be
enhanced when immune-suppressing forces within
the tumor microenvironment are rendered ineffective.
In collaboration with Michael J. Gough, Ph.D.,
associate member, Integrated Therapies Laboratory, she
is evaluating the role of a family of three cell-surface
receptors, Tyro3, Axl, and Mertk – or TAM, in tumor
immune suppression.
Studies show the activity of Axl and Mertk in the
tumor microenvironment prevents an effective anticancer immune response. Studies also demonstrated the
efficacy of radiation in eradicating tumors, and directing
anti-cancer immune responses toward residual cancer
cells found at the tumor site and throughout
the body.
In Emerging Topics in Life Sciences, Drs. Crittenden
and Gough report how the potential synergy of radiation
therapy with the loss or blockade of these receptors
could facilitate immune activation. “Inhibition of the
TAM family members is a potent therapeutic strategy to
initiate immune responses following radiation-induced
cancer cell death,” said Dr. Crittenden. Learn more about
the Integrated Therapies Lab on Page 14.

PUBLICATIONS:
Alice AF et al: Amplifying IFN-gamma signaling in
dendritic cells by CD11c-specific loss of SOCS1 increases
innate immunity to infection while decreasing adaptive
immunity. Journal of Immunology. 2018; 200(1):177185 [Epub 2017 Nov 17]. PMID: 29150567.
Baird JR et al: STING expression and response to
treatment with STING ligands in premalignant and
malignant disease. PLoS One. 2017; 12(11):e0187532.
PMID: 29135982.
Baird JR et al: Stimulating innate immunity to enhance
radiation therapy-induced tumor control. International
Journal of Radiation Oncology Biology Physics. 2017;
99(2):362-373. PMID: 28871985.
Patel AA et al. Early HPV-related base of tongue cancer.
In: Bell RB, Fernandes RP, Andersen PE, eds. Oral, Head
and Neck Oncology and Reconstructive Surgery. China:
Elsevier; 2017:649-76.
Sckisel GD et al: Differential phenotypes of memory
CD4 and CD8 T cells in the spleen and peripheral
tissues following immunostimulatory therapy. Journal
for ImmunoTherapy of Cancer. 2017; 5(33). PMID:
28428882.
Tormoen GW et al: The TAM family as a therapeutic
target in combination with radiation therapy. Emerging
Topics in Life Sciences. 2017; 1(5):493-500.
Weller M et al: Rindopepimut with temozolomide for
patients with newly diagnosed, EGFRvIII-expressing
glioblastoma (ACT IV): a randomised, double-blind,
international phase 3 trial. Lancet Oncology. 2017;
18(10):1373-1385. PMID: 28844499.
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STATE-OF-THE-ART SERVICES
With 45,000 square feet dedicated to cancer research, the Earle A.
Chiles Research Institute is home to several core facilities, offering our
investigators and collaborators the latest in immunological monitoring,
flow cytometry, immunohistochemistry, molecular pathology and
bioinformatics services.
BIOSPECIMEN REPOSITORY
For more than 20 years, we have maintained a Biospecimen Repository of malignant
and benign tissues donated by more than 1,000 patients. Containing more than 60,000
samples, nearly 80 types of cancer are represented from which our scientists perform
ongoing, novel research.
IMMUNE MONITORING LABORATORY
Our Immune Monitoring Laboratory is the archival and disbursement center for the
acquisition, processing, cryopreservation and cataloguing of all tumor tissue, peripheral
blood mononuclear cells and serum collected during the course of cancer clinical trials.
Together with the Flow Cytometry Core, the IML is a national leader in developing
and implementing immune monitoring assays for the evaluation of anti-tumor immune
responses in cancer patients receiving immunotherapy.
FLOW CYTOMETRY CORE
A heavily used and valuable resource, our Flow Cytometry Core allows investigators
to refine their immunotherapy strategies by measuring anti-tumor immune responses
on a cellular level. A component of the IML, the core is equipped with a BD Fortessa,
BD LSRII, Beckman Coulter Cytoflex, BD FACS Aria II Cell Sorter with BSL2
Containment System, BD FACS Calibur, CTL ImmunoSpot ELISpot, Luminex
Bio-Plex 100 and Guava PCA-96, among other instruments.
IMMUNO-HISTOLOGY CORE
Established in 2017 as a component of the IML, the Immuno-Histology Core performs
advanced tissue and image analyses in support of our preclinical and clinical studies. It

Our newest core facility, the Immuno-Histology Core provides investigators
at Providence Cancer Institute with advanced immunohistochemistry services.

contains a Vectra 3.0 Automated Quantitative Pathology Imaging System; a Zeiss Z1
Motorized Stage Fluorescence Microscope; a Sakura Tissue-Tek, Leica Embedder and
RM2235 Rotary Microtome for tissue processing, embedding and sectioning; Ventana
Discovery Ultra and Leica auto strainers; and a TMA Master for tissue microarray.
MOLECULAR PATHOLOGY CORE
A fundamental component of our translational research, the Molecular Pathology Core
provides investigators with molecular correlates to their research questions, enabling the
measurement of high-throughput omics projects with clinically validated bioinformatics
pipelines. Services include next-generation sequencing of whole exomes and RNA,
the analysis and quantification of circulating tumor DNA, mutation analysis with
neoantigen prediction and NanoString technology, and T-cell receptor analysis, among
other services.

EDUCATION & TRAININIG

TRAINING PROGRAMS
As part of our mission to train the next generation of immunologists,
the Earle A. Chiles Research Institute offers a rich training environment
with programs spanning the continuum of higher education, from
undergraduates to postdoctoral fellows.
SUMMER RESEARCH PROGRAM. An intensive nine-week internship for
undergraduate students, this program provides hands-on research experience and
mentorship for students pursuing careers in biomedical sciences. Interns complete
an independent research project and present their results at a capstone poster session.
They receive training in bioinformatics, and attend research seminars and meetings
where recent journal articles are reviewed and discussed. Past interns have been accepted
to the Mayo Clinic Graduate School of Biomedical Sciences, Northwestern University
School of Medicine and Oregon Health & Science University School of Medicine.
GRADUATE EDUCATION. Through partnerships with OHSU and universities
in China, graduate students conduct laboratory research under the guidance of our
faculty members with university appointments. Students have opportunities to give
poster presentations at national conferences and present their research at department
seminars while advancing to doctoral candidacy. Previous students have been accepted
to postdoctoral fellowships at the National Cancer Institute, INSERM (French National
Institute of Health and Medical Research) and within the biotechnology industry.
POSTDOCTORAL TRAINING. Seeking to acquire the professional skills and
experience necessary for independent scientific careers, fellows are mentored in cancer
immunotherapy expertise, research skill development, leadership, communication
and the responsible conduct of research. The pursuit of external funding and a strong
publication record are hallmarks of the program. Previous fellows have received
funding from the NIH Pathway to Independence Award, the American Cancer Society,
Susan G. Komen and the Prostate Cancer Foundation, and obtained appointments
at Rush University, Legacy Research Institute and OHSU.

PHOTO ABOVE RIGHT: 2017 Summer Research Program interns. RIGHT: Interns
present their research projects at a capstone poster session.
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BREAKTHROUGH TREATMENTS. TRANSFORMATIVE CARE.
Providence Cancer Institute offers patients the unique

n Survival outcomes for Providence patients surpass the national average.

advantages of both a world-class cancer research institute and a patientcentered community cancer program. From powerful, breakthrough
treatments to compassionate, transformative care and support, we
surround patients with everything they need for recovery and healing.

Unmatched experience, more clinical trials,
superior outcomes
Studies show that patients do better in centers that treat more people. Our experience
supports that:

Five-year relative survival rate: breast cancer
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2008-2014 and follow-up of patients into 2015. Survival rates have not been adjusted for
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Cancer patients in the Portland area (Multnomah, Clackamas and Washington counties)
who received some part of their cancer treatment at Providence Cancer Institute in 2017.

In 2017, more than 245 cancer research studies
were open to our patients, including 170 therapeutic
clinical trials and 48 phase I trials. More than 30 percent
of our adult patients participated in cancer research
studies, compared to 2 to 4 percent nationally.
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Compassionate support
In addition to powerful cancer therapies, we offer supportive care for
the body, mind and spirit. Providence patients have access to:
n Nurse navigators to guide them through their experiences
n Integrative care: acupuncture, naturopathy and massage therapy
n Social work services, including 1:1 counseling and in-person or

online English and Spanish support groups
n Nutrition advice from registered oncology dietitians
n Palliative care
n Financial counseling
n Extensive resources online at ProvidenceOregon.org/cancersupport

In 2017, we also produced a new series of videos to provide patients with
practical advice for coping with the common side effects of cancer and its
treatment. The videos feature Providence patients and providers, and can
be seen at ProvidenceOregon.org/livingwellvideos.

Lung cancer screenings:

Prevention and outreach
Providence Cancer Institute provided
cancer screenings to hundreds of
Oregonians in 2017 through outreach
programs aimed at detecting cancer in the
earliest stages, when it is most treatable.

678 new patients screened

599 head and neck
cancer screenings

160 skin cancer
screenings

1,430 total scans
28 cancers found

We also helped raise cancer awareness throughout the state by hosting
and participating in 33 community events in 2017.

Learn more about our clinics, services and events at ProvidenceOregon.org/cancer.
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Robert W. Franz Cancer Center named to honor Oregon philanthropist
A Portland native, Robert W. “Bob” Franz became a
passionate supporter of research to end cancer in 1986
when he joined the board of Providence Portland
Medical Foundation. His intense curiosity, generosity and
leadership played a major role in launching and furthering
cancer research efforts at Providence Portland Medical
Center, the future home of Providence Cancer Center.
EARLY SUPPORTER
Bob and his sister Elsie Franz Finley were early supporters
of Providence Cancer Center and its trailblazing successes
in the field of immunotherapy. Together, Bob and Elsie
quietly and consistently ensured Providence researchers
had the resources they needed to become international
leaders in immunotherapy for patients with cancer.
Immunotherapy boosts the body’s own defenses
against cancer by activating the immune system to find
and destroy tumors. This approach has been shown to be
effective in several types of advanced cancers, including
lung, bladder, lymphoma and kidney cancers, as well
as melanoma.
TRANSFORMATIONAL PHILANTHROPIST
With a lifetime of philanthropic support for cancer
research, Bob’s total giving to Providence Portland
Medical Foundation – $40 million – makes him the
single largest donor in Providence’s 142 years in Oregon.
Bob died in August 2016 and as a fitting and
lasting tribute to him and his legacy of contributions,
Providence Cancer Center – the 11-story tower that
houses cancer research and services – was renamed in

With the support of Providence and
people like Bob, our team is wellpositioned to show just how potent
immunotherapy can be in the
treatment of cancer.
his honor in October 2017. The facility is now the
Robert W. Franz Cancer Center, part of Providence
Cancer Institute.
The Franz estate gift will be used to attract more top
researchers from around the world, build new laboratory

and research space, and speed progress toward Providence’s
overarching goal to finish cancer in our lifetimes.
“Bob’s gift is transformative,” said Walter J. Urba,
M.D., Ph.D., member, director and endowed chair of
Cancer Research at the Earle A. Chiles Research Institute,
the research arm of the Robert W. Franz Cancer Center.
“It allows us to think about the future in ways we never
have before. With the support of Providence and people
like Bob, our team is well-positioned to show just how
potent immunotherapy can be in the treatment of cancer.”

A commemorative plaque depicting the transformational philanthropy of Robert W.
Franz greets patients and guests entering the cancer center named in his honor.
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Creating Hope
Research creates new treatments and new treatments create hope. That was the message
to the more than 500 supporters of Providence Cancer Institute who attended the
Providence Creating Hope Dinner on May 24, 2017.
The 19th annual Creating Hope dinner broke records, raising more than $778,000
in support of cancer research. Coupled with contributions from Safeway customers and
employees throughout the month of May, more than $1 million was raised for
translational cancer research.
The signature fundraising event for cancer research featured Diane Davis, a survivor of
ovarian cancer thanks to lifesaving immunotherapy she received as part of a first-inhuman clinical trial at Providence. Guests also heard from Bernard A. Fox, Ph.D., and
Eric Tran, Ph.D., faculty members of the Earle A. Chiles Research Institute, on the
importance of philanthropy in advancing treatments for cancer patients.

Team Runners4Research includes Providence Cancer Institute scientists, nurses,
doctors and friends.

Hood to Coast

ABOVE: Drs. Tran and Fox talk with emcee Helen
Raptis, thanking Providence donors for their
generous support. INSET: With her husband Jim,
Diane Davis shares why she is a cancer survivor
thanks to immunotherapy treatment and research
at Providence.

The 2017 Providence Hood to Coast Relay was a huge success, raising more than
$740,000 for cancer research at Providence. This is the fifth year the relay has been a
major fundraiser for Providence. Teams that fundraise are guaranteed one of the coveted
spots in the race. The top fundraising team for 2017 was All In, No Regrets. They raised
$42,495 for cancer research.
More than 1,000 running teams participated in the 199-mile race from Mt. Hood
to the coastal town of Seaside, Oregon. An additional 400 walking teams and 50 high
school teams covered the 130-mile Portland to Coast Relay.
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BY THE NUMBERS: 2017 FACTS AND FIGURES

Memberships & Collaborations
• Bristol Myers-Squibb
International Immuno-Oncology
Network
• NCI Community Oncology
Research Program via Pacific
Cancer Research Consortium
• NCI Cancer Immunotherapy
Trials Network

INVITED SEMINARS

• Partnership with MedImmune/
AstraZeneca for clinical
development of anti-OX40

l 13 visiting professor seminars
l 78 faculty extramural seminars

Investigators & Personnel

Institute Publications

19 faculty members
49 clinical researchers

142 total publications:
53 journal articles
10 books and book chapters
79 conference abstracts

63 lab researchers

Grant Funding, Sponsored
Research & Philanthropy

$4.5 million annually in

Clinical Trials
246 cancer clinical trials open
for enrollment, including

federal, private and sponsored
research funding

170 therapeutic trials and
48 phase I trials

$32.5 million raised by
Providence Foundations in Oregon
for Providence Cancer Institute

1,798 total enrollments

LEADERSHIP
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Faculty Members
R. Bryan Bell, M.D., D.D.S., FACS
Assistant member and medical director,
Providence Head and Neck Cancer
Program and Clinic
Head and Neck Oncologic Surgery
Carlo B. Bifulco, M.D.
Member and director,
Translational Molecular Pathology
Medical director, Molecular Genomics
Anatomic and Molecular Pathology
Alison K. Conlin, M.D., MPH
Associate member and medical director,
Providence Breast Cancer Medical
Program and High-Risk Breast Clinic
Medical Oncology

Franz Leadership Cabinet
Bernard A. Fox, Ph.D.
Member and Harder Family Endowed
Chair for Cancer Research, Molecular
and Tumor Immunology Laboratory
John E. Godwin, M.D., MS
Member and program leader,
Hematologic Malignancies
Medical Oncology
Michael J. Gough, Ph.D.
Associate member,
Integrated Therapies Laboratory
Hong-Ming Hu, Ph.D.
Associate member,
Cancer Immunobiology Laboratory

Marka R. Crittenden, M.D., Ph.D.
Associate member,
Integrated Therapies Laboratory
Director, Translational Radiation Research
Radiation Oncology

Rom S. Leidner, M.D.
Assistant member and co-director,
Providence Head and Neck Cancer
Program
Medical Oncology

Todd S. Crocenzi, M.D.
Associate member and director,
Gastrointestinal Oncology Research
Medical Oncology

Philippa H. Newell, M.D.
Assistant member and medical director,
Providence Liver Cancer Clinic
Liver and Pancreas Surgery

Brendan D. Curti, M.D.
Member and director,
Cytokine and Adoptive Immunotherapy
Program, Genitourinary Oncology
Research and Providence Melanoma
Program
Medical Oncology

David B. Page, M.D.
Assistant member,
Breast Cancer Immunotherapy
Medical Oncology
William L. Redmond, Ph.D.
Associate member,
Cancer Immunotherapy Laboratory
Director, Immune Monitoring Laboratory

Rachel E. Sanborn, M.D.
Associate member,
Phase I Clinical Trials Program
Co-director, Providence Thoracic
Oncology Program
Medical Oncology
Eric Tran, Ph.D.
Assistant member,
Antitumor T-cell Response Laboratory
Walter J. Urba, M.D., Ph.D.
Member, director and endowed chair
of Cancer Research
Medical Oncology
Andrew D. Weinberg, Ph.D.
Member and Judith Ann Hartmann
Endowed Chair for the Laboratory
of Basic Immunology
Kristina H. Young, M.D., Ph.D.
Assistant member,
Tumor Microenvironment Laboratory
Radiation Oncology

Administration
Julie Cramer, MA, CCRP
Administrative director,
Cancer Clinical Research
Samantha Kaiser
Director, Cancer Research Operations

The Robert W. Franz Cancer Leadership
Cabinet comprises men and women
with a desire to connect the Portland
metropolitan community with the
dedicated teams of researchers working
to finish cancer at the Earle A. Chiles
Research Institute. Founded in 2001, the
leadership cabinet has a strong and loyal
membership representing a broad
spectrum of the community.
2017 CABINET MEMBERS
TJ O’Connor, chair
Flo Atkinson
Stephen Bader, M.D.
Mark Beckius
Walter C. Bowen
Kay Carlisle
Charlie Engelberg
Dan Floyd
Pedro Garcia
Diana Hall
Cindy Harder
Dan Kinney
Sheryl Langerman Rosenfeld
Lynn Loacker
Patricia Markesino
Nicole McIntyre
Jooyon K. “Julieann” Park
Linda Read
James F. Robb, Ph.D.
Linda Smiley
Mark Williams
Linda Yoshida

OUR MISSION
As expressions of God’s healing love,
witnessed through the ministry of Jesus,
we are steadfast in serving all, especially
those who are poor and vulnerable.
OUR VALUES
Compassion, Dignity, Justice
Excellence, Integrity

chilesresearch.org

